The history and future of targeting cyclin-dependent ki

Nature Reviews Drug Discovery
14, 130-146
DOI: 10.1038/nrd4504

Citation Report

#	Article	IF	Citations
2	MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1. Molecular Medicine Reports, 2015, 12, 4647-4651.	1.1	41
4	KRAS mutant lung cancer: progress thus far on an elusive therapeutic target. Clinical and Translational Medicine, 2015, 4, 35.	1.7	45
5	The IMPAKT of breast cancer research: fundamental science and applied medicine. Future Science OA, 2015, 1, FSO69.	0.9	0
6	RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy. Oncotarget, 2015, 6, 17873-17890.	0.8	125
7	Traditional Ayurvedic medicines: Pathway to develop anti-cancer drugs. Journal of Molecular Pharmaceutics & Organic Process Research, 2015, 03, .	2.0	4
8	Breast cancer: Are we in the best era?. Asian Journal of Oncology, 0, 01, 063-064.	0.2	0
9	Palbociclib in Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2015, 373, 209-219.	13.9	1,239
10	CDK8 kinaseâ€”An emerging target in targeted cancer therapy. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 1617-1629.	1.1	56
11	Molecular Pathways: Targeting the Cyclin Dâ€“CDK4/6 Axis for Cancer Treatment. Clinical Cancer Research, 2015, 21, 2905-2910.	3.2	307
12	Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 993-1009.	0.9	2
13	Hitting the brakes: targeting microtubule motors in cancer. British Journal of Cancer, 2015, 113, 693-698.	2.9	72
14	Cell Cycle Related Kinases. , 2015, , 1-8.		0
15	Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 953-970.	2.4	38
16	Roscovitine treatment caused impairment of fertilizing ability in mice. Toxicology Letters, 2015, 237, 200-209.	0.4	3
17	Irinotecan Induces Cell Cycle Arrest, but Not Apoptosis or Necrosis, in Caco-2 and CW2 Colorectal Cancer Cell Lines. Pharmacology, 2015, 95, 154-159.	0.9	12
18	Cell cycle gene expression networks discovered using systems biology: Significance in carcinogenesis. Journal of Cellular Physiology, 2015, 230, 2533-2542.	2.0	16
19	SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends in Biochemical Sciences, 2015, 40, 779-793.	3.7	216
20	Less Can Be More for Gene Dose and Drug Sensitivity. Clinical Cancer Research, 2015, 21, 4750-4752.	3.2	0

#	Article	IF	Citations
21	Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opinion on Pharmacotherapy, 2015, 16, 2023-2037.	0.9	1
22	Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. ACS Chemical Biology, 2015, 10, 2680-2686.	1.6	68
23	Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Seminars in Oncology, 2015, 42, 788-800.	0.8	101
24	The dynamic control of signal transduction networks in cancer cells. Nature Reviews Cancer, 2015, 15, 515-527.	12.8	282
25	Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor. Molecular Cell, 2015, 59, 513-514.	4.5	18
26	The steady progress of targeted therapies, promising advances for lung cancer. Ecancermedicalscience, 2016, 10, 638.	0.6	6
27	Profile of palbociclib in the treatment of metastatic breast cancer. Breast Cancer: Targets and Therapy, 2016, 8, 83.	1.0	8
28	Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. Ecancermedicalscience, 2016, 10, 609.	0.6	30
29	An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. Oncotarget, 2016, 7, 51163-51173.	0.8	15
30	High Expression of PTGR1 Promotes NSCLC Cell Growth via Positive Regulation of Cyclin-Dependent Protein Kinase Complex. BioMed Research International, 2016, 2016, 1-12.	0.9	10
31	Virtual Screening for Potential Allosteric Inhibitors of Cyclin-Dependent Kinase 2 from Traditional Chinese Medicine. Molecules, 2016, 21, 1259.	1.7	14
32	Maintaining Genome Stability in Defiance of Mitotic DNA Damage. Frontiers in Genetics, 2016, 7, 128.	1.1	4
33	Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of Î±-Tubulin and Inhibition of Microtubule Formation. Molecules, 2016, 21, 374.	1.7	24
34	Novel Molecular Markers for Breast Cancer. Biomarkers in Cancer, 2016, 8, BIC.S38394.	3.6	45
35	miR-18a promotes cell proliferation of esophageal squamous cell carcinoma cells by increasing cylin D1 via regulating PTEN-PI3K-AKT-mTOR signaling axis. Biochemical and Biophysical Research Communications, 2016, 477, 144-149.	1.0	43
36	Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma. Molecular Cancer Research, 2016, 14, 928-940.	1.5	53
37	The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 61-66.	2.0	21
38	Sensitization strategies in lung cancer. Oncology Letters, 2016, 12, 3669-3673.	0.8	2

#	Article	IF	Citations
39	New Approaches to Managing Liposarcoma: Will Cold Steel Remain the Only Way to Heal?. Journal of Oncology Practice, 2016, 12, 230-231.	2.5	1
40	Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer. EBioMedicine, 2016, 14, 44-54.	2.7	36
41	Treating cancer with selective CDK4/6 inhibitors. Nature Reviews Clinical Oncology, 2016, 13, 417-430.	12.5	806
42	Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nature Reviews Molecular Cell Biology, 2016, 17, 280-292.	16.1	389
43	Anticancer Potential of Spider Venom. , 2016, , 293-311.		1
44	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptorâ€“Positive Breast Cancer. Cancer Research, 2016, 76, 2301-2313.	0.4	509
45	Jumping the nuclear envelope barrier: Improving polyplex-mediated gene transfection efficiency by a selective CDK1 inhibitor RO-3306. Journal of Controlled Release, 2016, 234, 90-97.	4.8	12
46	Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel. Molecular Cancer Therapeutics, 2016, 15, 1691-1701.	1.9	31
47	Identification of azepinone fused tetracyclic heterocycles as new chemotypes with protein kinase inhibitory activities. Tetrahedron, 2016, 72, 2376-2385.	1.0	15
48	Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis. Frontiers of Medicine, 2016, 10, 183-190.	1.5	52
49	Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9. ACS Chemical Biology, 2016, 11, 1710-1719.	1.6	61
50	Cell Cycle Regulation and Melanoma. Current Oncology Reports, 2016, 18, 34.	1.8	48
51	Emerging targeted therapies for melanoma. Expert Opinion on Emerging Drugs, 2016, 21, 195-207.	1.0	22
52	Paradoxical roles of cyclin D1 in DNA stability. DNA Repair, 2016, 42, 56-62.	1.3	20
53	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€“Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology, 2016, 34, 2602-2609.	0.8	101
54	CDK1/2 toolbox in need of an upgrade. Cell Cycle, 2016, 15, 1663-1664.	1.3	0
55	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry, 2016, 59, 8667-8684.	2.9	121
56	Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2016, 15, 1682-1690.	1.9	31

#	Article	IF	Citations
57	The Emerging Role of Cdk5 in Cancer. Trends in Cancer, 2016, 2, 606-618.	3.8	128
58	Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell Death and Disease, 2016, 7, e2389-e2389.	2.7	119
59	Information theoretic sub-network mining characterizes breast cancer subtypes in terms of cancer core mechanisms. Journal of Bioinformatics and Computational Biology, 2016, 14, 1644002.	0.3	2
60	Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb. Cancer Biology and Therapy, 2016, 17, 1197-1205.	1.5	24
61	Genomic insights into head and neck cancer. Cancers of the Head & Neck, 2016, 1, .	6.2	65
62	miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6. Biomedicine and Pharmacotherapy, 2016, 83, 792-797.	2.5	58
63	Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors. European Journal of Pharmacology, 2016, 789, 280-290.	1.7	13
64	Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Molecular Cancer Therapeutics, 2016, 15, 2273-2281.	1.9	294
65	EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Molecular Cancer Therapeutics, 2016, 15, 2486-2497.	1.9	42
66	Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care, 2016, 11, 167-173.	0.8	92
67	PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicology and Applied Pharmacology, 2016, 310, 9-19.	1.3	33
68	Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacologica Sinica, 2016, 37, 1481-1489.	2.8	30
69	A Dynamical Framework for the All-or-None G1/S Transition. Cell Systems, 2016, 2, 27-37.	2.9	115
70	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. British Journal of Cancer, 2016, 115, 682-690.	2.9	40
71	A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research, 2016, 22, 5696-5705.	3.2	245
72	Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. Expert Review of Clinical Pharmacology, 2016, 9, 1153-1161.	1.3	8
73	Elevated E2F7 expression predicts poor prognosis in human patients with gliomas. Journal of Clinical Neuroscience, 2016, 33, 187-193.	0.8	18
74	Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). Expert Opinion on Investigational Drugs, 2016, 25, 1215-1230.	1.9	24

#	Article	IF	Citations
75	Antiâ€angiogenic effects of novel cyclinâ€dependent kinase inhibitors with a pyrazolo[4,3â€d]pyrimidine scaffold. British Journal of Pharmacology, 2016, 173, 2645-2656.	2.7	8
76	CDK4/6 inhibition in luminal breast cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 76-81.	0.3	8
77	Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine. BMC Genomics, 2016, 17, 455.	1.2	7
78	Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Journal of Medicinal Chemistry, 2016, 59, 10030-10066.	2.9	106
79	Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. Future Medicinal Chemistry, 2016, 8, 2047-2076.	1.1	10
80	Novel Strategies in Hormone Receptor-Positive Advanced Breast Cancer: Overcoming Endocrine Resistance. Current Breast Cancer Reports, 2016, 8, 193-205.	0.5	2
81	Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. Cancer Journal (Sudbury, Mass), 2016, 22, 267-273.	1.0	9
82	High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptorâ€“Positive Metastatic Breast Cancer. Clinical Cancer Research, 2016, 22, 5514-5526.	3.2	57
83	Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression. Molecular and Cellular Oncology, 2016, 3, e1090048.	0.3	8
84	GermlineCDKN2AMutation Status and Survival in Familial Melanoma Cases. Journal of the National Cancer Institute, 2016, 108, djw135.	3.0	47
85	Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. Clinical Cancer Research, 2016, 22, 6061-6068.	3.2	99
86	Toward precision medicine of breast cancer. Theoretical Biology and Medical Modelling, 2016, 13, 7.	2.1	48
87	Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods. Journal of Molecular Graphics and Modelling, 2016, 68, 57-67.	1.3	3
88	Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. MedChemComm, 2016, 7, 1580-1586.	3.5	19
89	Cyclinâ€Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future. Pharmacotherapy, 2016, 36, 652-667.	1.2	48
90	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer, 2016, 115, 303-311.	2.9	27
91	TPâ€2Rho Is a Sensitive Solvatochromic Redâ€Shifted Probe for Monitoring the Interactions between CDK4 and Cyclinâ€…D. ChemBioChem, 2016, 17, 737-744.	1.3	6
92	Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 354-365.	1.3	35

#	Article	IF	Citations
93	Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Reports, 2016, 14, 979-990.	2.9	160
94	Mitigating the Risk of Coprecipitation of Pinacol during Isolation from Telescoped Miyaura Borylation and Suzuki Couplings Utilizing Boron Pinacol Esters: Use of Modeling for Process Design. Organic Process Research and Development, 2016, 20, 178-188.	1.3	14
95	Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discovery, 2016, 6, 353-367.	7.7	717
96	CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer. Cancer Cell, 2016, 29, 243-244.	7.7	9
97	Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacological Research, 2016, 107, 249-275.	3.1	179
98	Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1. Cell Cycle, 2016, 15, 1184-1188.	1.3	19
99	Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms. American Journal of Pathology, 2016, 186, 671-677.	1.9	40
100	Cancer TARGETases: DSB repair as a pharmacological target. , 2016, 161, 111-131.		21
101	Targeting protein kinases to reverse multidrug resistance in sarcoma. Cancer Treatment Reviews, 2016, 43, 8-18.	3.4	19
102	5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. European Journal of Medicinal Chemistry, 2016, 110, 291-301.	2.6	29
103	Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Molecular Cancer Therapeutics, 2016, 15, 783-793.	1.9	79
104	Underlying mechanisms of cyclic peptide inhibitors interrupting the interaction of CK2Î±/CK2Î²: comparative molecular dynamics simulation studies. Physical Chemistry Chemical Physics, 2016, 18, 9202-9210.	1.3	25
105	Medical Management of Meningiomas. Neurosurgery Clinics of North America, 2016, 27, 249-260.	0.8	36
106	Chemical fragment-based CDK4/6 inhibitors prediction and web server. RSC Advances, 2016, 6, 16972-16981.	1.7	11
107	Expression and Clinical Role of Cdc5L as a Novel Cell Cycle Protein in Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 795-805.	1.1	23
108	Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond. Future Medicinal Chemistry, 2016, 8, 55-72.	1.1	5
109	Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors. European Journal of Medicinal Chemistry, 2016, 108, 701-719.	2.6	33
110	Efficient synthesis of novel disubstituted pyrido[3,4-b]pyrazines for the design of protein kinase inhibitors. MedChemComm, 2016, 7, 224-229.	3.5	5

#	Article	IF	Citations
111	CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1. Journal of Urology, 2016, 195, 771-779.	0.2	38
112	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology, 2016, 150, 48-63.	0.6	90
113	The effect of miR-340 over-expression on cell-cycle-related genes in triple-negative breast cancer cells. European Journal of Cancer Care, 2017, 26, e12496.	0.7	22
114	Multi-step virtual screening to develop selective DYRK1A inhibitors. Journal of Molecular Graphics and Modelling, 2017, 72, 229-239.	1.3	10
115	Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?. Expert Opinion on Investigational Drugs, 2017, 26, 207-217.	1.9	17
116	CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nature Communications, 2017, 8, 13923.	5.8	119
117	Design, synthesis, biological evaluation, and 3Dâ€‹<scp>QSAR</scp> analysis of podophyllotoxinâ€“dioxazole combination as tubulin targeting anticancer agents. Chemical Biology and Drug Design, 2017, 90, 236-243.	1.5	15
118	Cell cycle proteins as promising targets in cancer therapy. Nature Reviews Cancer, 2017, 17, 93-115.	12.8	1,418
119	Structural Basis of the Interaction of Cyclinâ€Dependent Kinaseâ€…2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles. ChemPhysChem, 2017, 18, 785-795.	1.0	14
120	Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates. ChemMedChem, 2017, 12, 487-501.	1.6	151
121	Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3â€²,4â€²:3,4]benzo[1,2- d]isothiazole derivatives. Bioorganic and Medicinal Chemistry, 2017, 25, 2336-2350.	1.4	30
123	The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends in Cancer, 2017, 3, 39-55.	3.8	206
124	Rapamycin treatment doseâ€dependently improves the cystic kidney in a new <scp>ADPKD</scp> mouse model via the <scp>mTORC</scp>1 and cellâ€cycleâ€associated <scp>CDK</scp>1/cyclin axis. Journal of Cellular and Molecular Medicine, 2017, 21, 1619-1635.	1.6	33
125	An insight into the inhibitory selectivity of 4-(Pyrazol- 4-yl)-pyrimidines to CDK4 over CDK2. Molecular Simulation, 2017, 43, 599-609.	0.9	3
126	Inhibitors of cyclin-dependent kinases as cancer therapeutics. , 2017, 173, 83-105.		278
127	Transcriptomes reflect the phenotypes of undifferentiated, granulocyte and macrophage forms of HL-60/S4 cells. Nucleus, 2017, 8, 222-237.	0.6	19
128	Targeting kinase signaling pathways with constrained peptide scaffolds. , 2017, 173, 159-170.		14
129	Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell, 2017, 31, 576-590.e8.	7.7	84

#	Article	IF	Citations
130	Targeting Cyclin-Dependent Kinases in Ovarian Cancer. Cancer Investigation, 2017, 35, 367-376.	0.6	20
131	Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treatment Reviews, 2017, 56, 28-35.	3.4	57
132	Iron and thiol redox signaling in cancer: An exquisite balance to escape ferroptosis. Free Radical Biology and Medicine, 2017, 108, 610-626.	1.3	180
133	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 2017, 23, 2433-2441.	3.2	134
134	CDC5L Promotes hTERT Expression and Colorectal Tumor Growth. Cellular Physiology and Biochemistry, 2017, 41, 2475-2488.	1.1	37
135	Antitumor effects and the underlying mechanism of licochalcone A combined with 5-fluorouracil in gastric cancer cells. Oncology Letters, 2017, 13, 1695-1701.	0.8	19
136	Epigenetic assays for chemical biology and drug discovery. Clinical Epigenetics, 2017, 9, 41.	1.8	25
137	Accurate Prediction of Complex Structure and Affinity for a Flexible Protein Receptor and Its Inhibitor. Journal of Chemical Theory and Computation, 2017, 13, 2389-2399.	2.3	43
138	Investigation of differentially-expressed microRNAs and genes in cervical cancer using an integrated bioinformatics analysis. Oncology Letters, 2017, 13, 2784-2790.	0.8	16
139	MYCN induces neuroblastoma in primary neural crest cells. Oncogene, 2017, 36, 5075-5082.	2.6	76
140	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer, 2017, 116, 1505-1512.	2.9	25
141	High-content analysis screening for cell cycle regulators using arrayed synthetic crRNA libraries. Journal of Biotechnology, 2017, 251, 189-200.	1.9	25
142	Cell Cycle-Dependent Kinase Cdk9 Is a Postexposure Drug Target against Human Adenoviruses. ACS Infectious Diseases, 2017, 3, 398-405.	1.8	13
143	Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Science Translational Medicine, 2017, 9, .	5.8	107
144	Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology and Oncology, 2017, 10, 97.	6.9	126
145	Palbociclib induces activation of <scp>AMPK</scp> and inhibits hepatocellular carcinoma in a <scp>CDK</scp>4/6â€independent manner. Molecular Oncology, 2017, 11, 1035-1049.	2.1	52
146	Multi-site Neurogenin3 Phosphorylation Controls Pancreatic Endocrine Differentiation. Developmental Cell, 2017, 41, 274-286.e5.	3.1	67
147	Endometrial Carcinoma: Specific Targeted Pathways. Advances in Experimental Medicine and Biology, 2017, 943, 149-207.	0.8	53

#	Article	IF	Citations
148	Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3231-3237.	1.0	25
149	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs, 2017, 77, 1313-1336.	4.9	39
150	MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in MetastaticÂMelanoma. Journal of Investigative Dermatology, 2017, 137, 1955-1964.	0.3	32
151	Emerging cell cycle inhibitors for acute myeloid leukemia. Expert Opinion on Emerging Drugs, 2017, 22, 137-148.	1.0	13
152	MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death and Disease, 2017, 8, e2895-e2895.	2.7	226
153	Cell Cycle-Related Kinases. , 2017, , 989-996.		0
154	Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition. Journal of Biological Chemistry, 2017, 292, 11727-11739.	1.6	59
155	Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer. Molecular Cancer Therapeutics, 2017, 16, 1739-1750.	1.9	58
156	<scp>CDK</scp>4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Molecular Medicine, 2017, 9, 1052-1066.	3.3	65
157	Unbalanced Growth, Senescence and Aging. Advances in Experimental Medicine and Biology, 2017, 1002, 189-208.	0.8	13
158	Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 5561-5572.	3.2	198
159	JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21. Oncogene, 2017, 36, 4349-4361.	2.6	26
160	Dihydromyricetin protects against cerebral ischemia/reperfusion injury via suppressing microglia-mediated neuroinflammation and activation of ERK1/2-CREB signaling pathway. Journal of Functional Foods, 2017, 33, 76-84.	1.6	15
161	Palbociclib has antitumour effects on Ptenâ€deficient endometrial neoplasias. Journal of Pathology, 2017, 242, 152-164.	2.1	25
162	Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer. Cell Reports, 2017, 18, 3242-3256.	2.9	81
163	Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clinical Cancer Research, 2017, 23, 3251-3262.	3.2	175
164	Synthesis and antiproliferative evaluation of novel azido nucleosides and their phosphoramidate derivatives. Pure and Applied Chemistry, 2017, 89, 1267-1281.	0.9	5
165	Molecular mechanisms and therapeutic targets in pediatric brain tumors. Science Signaling, 2017, 10, .	1.6	53

#	Article	IF	Citations
166	Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer. Scientific Reports, 2017, 7, 44021.	1.6	31
167	CDK4/6 inhibitors in HER2-positive breast cancer. Critical Reviews in Oncology/Hematology, 2017, 112, 208-214.	2.0	44
168	Cyclin-Dependent Kinase (CDK) Inhibitors: Structureâ€“Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry, 2017, 60, 1746-1767.	2.9	77
169	Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth. Molecular Cancer Research, 2017, 15, 237-249.	1.5	71
170	Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines. European Journal of Medicinal Chemistry, 2017, 126, 1118-1128.	2.6	32
171	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut, 2017, 66, 1286-1296.	6.1	198
172	CDK5 in oncology: recent advances and future prospects. Future Medicinal Chemistry, 2017, 9, 1939-1962.	1.1	36
173	Identification of Atuveciclib (BAYâ€…1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem, 2017, 12, 1776-1793.	1.6	135
174	Genomics and advances towards precision medicine for head and neck squamous cell carcinoma. Laryngoscope Investigative Otolaryngology, 2017, 2, 310-319.	0.6	12
175	Therapeutic Approaches for Zika Virus Infection of the Nervous System. Neurotherapeutics, 2017, 14, 1027-1048.	2.1	25
176	Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma. Cancer Research, 2017, 77, 6614-6626.	0.4	103
177	Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin. European Journal of Medicinal Chemistry, 2017, 141, 584-595.	2.6	23
178	Receptorâ€guided <scp>3D</scp>â€Quantitative Structureâ€“Activity Relationship and Docking Studies of 6â€Substituted 2â€Arylaminopurines as <scp>CDK2</scp> Kinase Inhibitors. Bulletin of the Korean Chemical Society, 2017, 38, 1275-1284.	1.0	2
179	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. Clinical Cancer Research, 2017, 23, 7006-7019.	3.2	61
180	Emerging treatments and personalised medicine for ciliopathies associated with cystic kidney disease. Expert Opinion on Orphan Drugs, 2017, 5, 785-798.	0.5	9
181	Down regulation of the long non-coding RNA PCAT-1 induced growth arrest and apoptosis of colorectal cancer cells. Life Sciences, 2017, 188, 37-44.	2.0	42
182	Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. British Journal of Cancer, 2017, 117, 1258-1268.	2.9	42
183	Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. Human Mutation, 2017, 38, 1621-1648.	1.1	82

#	Article	IF	Citations
184	Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert Review of Clinical Pharmacology, 2017, 10, 1169-1176.	1.3	9
185	Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4. Gene, 2017, 635, 3-8.	1.0	22
186	Network-based modelling and percolation analysis of conformational dynamics and activation in the CDK2 and CDK4 proteins: dynamic and energetic polarization of the kinase lobes may determine divergence of the regulatory mechanisms. Molecular BioSystems, 2017, 13, 2235-2253.	2.9	7
187	Linarin suppresses glioma through inhibition of NF-Î¹B/p65 and up-regulating p53 expression in vitro and in vivo. Biomedicine and Pharmacotherapy, 2017, 95, 363-374.	2.5	31
188	Multiomics Analysis of Tumor Microenvironment Reveals Gata2 and miRNA-124-3p as Potential Novel Biomarkers in Ovarian Cancer. OMICS A Journal of Integrative Biology, 2017, 21, 603-615.	1.0	42
189	A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer. Scientific Reports, 2017, 7, 10228.	1.6	11
190	Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. European Journal of Medicinal Chemistry, 2017, 142, 424-458.	2.6	56
191	Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. British Journal of Cancer, 2017, 117, 572-582.	2.9	26
192	Advances of small molecule targeting of kinases. Current Opinion in Chemical Biology, 2017, 39, 126-132.	2.8	44
193	Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 363-369.	1.1	3
194	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist, 2017, 22, 1039-1048.	1.9	115
195	TRAP1 controls cell cycle G2â€“M transition through the regulation of CDK1 and MAD2 expression/ubiquitination. Journal of Pathology, 2017, 243, 123-134.	2.1	34
196	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Future Oncology, 2017, 13, 2137-2149.	1.1	7
197	Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. Clinical Cancer Research, 2017, 23, 6958-6968.	3.2	74
198	Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4399-4404.	1.0	9
199	Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Molecular Cell, 2017, 68, 1134-1146.e6.	4.5	73
200	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. Breast Care, 2017, 12, 296-302.	0.8	8
201	Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach. Computational Biology and Chemistry, 2017, 71, 224-229.	1.1	21

#	Article	IF	Citations
202	Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. Journal of Medicinal Chemistry, 2017, 60, 9470-9489.	2.9	39
203	Targeting the CDK4/6 Pathway in Breast Cancer. , 2017, , 807-817.		0
204	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care, 2017, 12, 304-308.	0.8	53
205	Identification of cell cycle-targeting microRNAs through genome-wide screens. Cell Cycle, 2017, 16, 2241-2248.	1.3	7
207	Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. British Journal of Cancer, 2017, 117, 409-420.	2.9	88
208	Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma. Blood, 2017, 130, 1114-1124.	0.6	59
209	Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6231-E6239.	3.3	74
210	Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 2017, 17, 851-856.	1.1	30
211	Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells. Cell Cycle, 2017, 16, 1453-1464.	1.3	30
212	Targeting mitotic pathways for endocrine-related cancer therapeutics. Endocrine-Related Cancer, 2017, 24, T65-T82.	1.6	4
213	The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leukemia and Lymphoma, 2017, 58, 1358-1365.	0.6	35
214	Synchronization and Desynchronization of Cells by Interventions on the Spindle Assembly Checkpoint. Methods in Molecular Biology, 2017, 1524, 77-95.	0.4	2
215	An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold. European Journal of Medicinal Chemistry, 2017, 126, 298-352.	2.6	127
216	Negative regulation of type I <scp>IFN</scp> signaling by phosphorylation of <scp>STAT</scp> 2 on T387. EMBO Journal, 2017, 36, 202-212.	3.5	27
217	Approved and Experimental Smallâ€Molecule Oncology Kinase Inhibitor Drugs: A Midâ€2016 Overview. Medicinal Research Reviews, 2017, 37, 314-367.	5.0	65
218	A CDK2 activity signature predicts outcome in CDK2-low cancers. Oncogene, 2017, 36, 2491-2502.	2.6	32
219	Cell Cycleâ€"Targeted Cancer Therapies. Annual Review of Cancer Biology, 2017, 1, 41-57.	2.3	88
220	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clinical Cancer Research, 2017, 23, 1862-1874.	3.2	107

#	Article	IF	Citations
221	Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Annals of Oncology, 2017, 28, 44-56.	0.6	43
222	Metal-Containing Pharmacophores in Molecularly Targeted Anticancer Therapies and Diagnostics. European Journal of Inorganic Chemistry, 2017, 2017, 1561-1572.	1.0	15
223	Cell Cycle Regulation in Treatment of Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 251-270.	0.8	20
224	miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14. Cell Death and Disease, 2017, 8, e3103-e3103.	2.7	74
225	BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Reports, 2017, 21, 3398-3405.	2.9	130
226	CDK4/6 Inhibitors in Cancer Therapy: AÂNovel Treatement Strategy for Bladder Cancer. Bladder Cancer, 2017, 3, 79-88.	0.2	21
227	CDKL1 promotes tumor proliferation and invasion in colorectal cancer. OncoTargets and Therapy, 2017, Volume 10, 1613-1624.	1.0	13
228	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. , 2017, , 1-38.		1
229	HR+, HER2â€“ Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. Current Cancer Drug Targets, 2017, 17, 637-649.	0.8	65
230	Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays in Biochemistry, 2017, 61, 439-452.	2.1	39
231	Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases. International Journal of Molecular Sciences, 2017, 18, 2292.	1.8	7
232	Microfluidic Cell Cycle Analysis of Spread Cells by DAPI Staining. Micromachines, 2017, 8, 36.	1.4	9
233	Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. Viruses, 2017, 9, 13.	1.5	8
234	Drug discovery. , 2017, , 281-420.		1
235	Transcription Factors in Breast Cancerâ€”Lessons From Recent Genomic Analyses and Therapeutic Implications. Advances in Protein Chemistry and Structural Biology, 2017, 107, 223-273.	1.0	14
236	AR Signaling in Breast Cancer. Cancers, 2017, 9, 21.	1.7	81
237	Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 2017, 9, 52.	1.7	1,153
238	Modeling and Targeting MYC Genes in Childhood Brain Tumors. Genes, 2017, 8, 107.	1.0	22

#	Article	IF	Citations
239	MYC Modulation around the CDK2/p27/SKP2 Axis. Genes, 2017, 8, 174.	1.0	58
240	Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences, 2017, 18, 778.	1.8	27
241	Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. International Journal of Molecular Sciences, 2017, 18, 779.	1.8	63
242	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. Frontiers in Oncology, 2017, 7, 50.	1.3	30
243	Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737. General Physiology and Biophysics, 2017, 36, 539-547.	0.4	8
244	A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. PLoS ONE, 2017, 12, e0172315.	1.1	36
245	The emerging roles of CDK12 in tumorigenesis. Cell Division, 2017, 12, 7.	1.1	61
246	Structural prediction of the interaction of the tumor suppressor p27KIP1 with cyclin A/CDK2 identifies a novel catalytically relevant determinant. BMC Bioinformatics, 2017, 18, 15.	1.2	5
247	Increasing the Potential Targets and Molecularly Targeted Agent Combinations Against Cancer Cell Proliferation. Journal of Cell Signaling, 2017, 02, .	0.3	1
248	Autophagy is essential for flavopiridol-induced cytotoxicity against MCF-7 breast cancer cells. Molecular Medicine Reports, 2017, 16, 9715-9720.	1.1	9
249	Recent Advances on Nucleotide Analogs and Mimetics. , 2017, , .		2
250	Lentivirus-mediated knockdown of P27RF-Rho inhibits hepatocellular carcinoma cell growth. Wspolczesna Onkologia, 2017, 1, 35-41.	0.7	3
251	Identification of novel genetic etiology and key molecular pathways for seminoma via network-based studies. International Journal of Oncology, 2017, 51, 1280-1290.	1.4	13
252	Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signature. Oncotarget, 2017, 8, 43678-43691.	0.8	53
253	EMODIN DOWNREGULATES CELL PROLIFERATION MARKERS DURING DMBA INDUCED ORAL CARCINOGENESIS IN GOLDEN SYRIAN HAMSTERS. Tropical Journal of Obstetrics and Gynaecology, 2017, 14, 83-91.	0.3	8
254	A Brief History of Eukaryotic Cell Cycle Research. Plant Cell Monographs, 2018, , 67-93.	0.4	2
255	Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells. Investigational New Drugs, 2018, 36, 961-969.	1.2	16
256	Discovery of novel CDK inhibitors via scaffold hopping from CAN508. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1386-1391.	1.0	16

#	Article	IF	Citations
257	Highâ€Throughput Kinetic Analysis for Targetâ€Directed Covalent Ligand Discovery. Angewandte Chemie - International Edition, 2018, 57, 5257-5261.	7.2	59
258	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoc as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer. Journal of Medicinal Chemistry, 2018, 61, 3166-3192.	2.9	63
259	Highâ€Throughput Kinetic Analysis for Targetâ€Directed Covalent Ligand Discovery. Angewandte Chemie, 2018, 130, 5355-5359.	1.6	5
260	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist, 2018, 23, 586-593.	1.9	75
261	Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factorâ€Î² type I receptor/apoptosis signalâ€regulating kinase 1/mitogenâ€activated protein kinase signaling axis. Cancer Science, 2018, 109, 642-655.	1.7	31
262	CCRK is a novel signalling hub exploitable in cancer immunotherapy. , 2018, 186, 138-151.		35
263	Guiding Mitotic Progression by Crosstalk between Post-translational Modifications. Trends in Biochemical Sciences, 2018, 43, 251-268.	3.7	43
264	Imidazo[1,2â€c]pyrimidinâ€5(6H)â€one as a novel core of cyclinâ€dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring. Journal of Molecular Recognition, 2018, 31, e2720.	1.1	10
265	A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?. BioEssays, 2018, 40, e1700243.	1.2	18
266	Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1573-1582.	1.8	45
267	Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell Reports, 2018, 22, 1185-1199.	2.9	71
268	Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer. Annals of Oncology, 2018, 29, 535-537.	0.6	8
269	PolyC-binding proteins enhance expression of the CDK2 cell cycle regulatory protein via alternative splicing. Nucleic Acids Research, 2018, 46, 2030-2044.	6.5	15
270	Kinase-independent function of E-type cyclins in liver cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1015-1020.	3.3	32
271	Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 299-305.	0.9	4
272	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-car (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. Journal of Medicinal Chemistry, 2018, 61, 1499-1518.	2.9	72
273	PRC1: Linking Cytokinesis, Chromosomal Instability, and Cancer Evolution. Trends in Cancer, 2018, 4, 59-73.	3.8	59
274	Structureâ€Based Design of Selective Noncovalent CDK12 Inhibitors. ChemMedChem, 2018, 13, 231-235.	1.6	37

#	Article	IF	Citations
275	Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells. Molecular Cancer Research, 2018, 16, 361-377.	1.5	48
276	Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4. Oncogene, 2018, 37, 1685-1698.	2.6	45
277	PAQR4 has a tumorigenic effect in human breast cancers in association with reduced CDK4 degradation. Carcinogenesis, 2018, 39, 439-446.	1.3	24
278	CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell, 2018, 34, 9-20.	7.7	300
279	Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival. Applied Cancer Research, 2018, 38, .	1.0	2
280	3-Nitroacridine derivatives arrest cell cycle at G0/G1 phase and induce apoptosis in human breast cancer cells may act as DNA-target anticancer agents. Life Sciences, 2018, 206, 1-9.	2.0	21
281	Selective and novel cyclin-dependent kinases 4 inhibitor: synthesis and biological evaluation. Medicinal Chemistry Research, 2018, 27, 1666-1678.	1.1	4
282	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21.	0.9	21
283	Design, synthesis, and molecular docking study of 3Hâ€imidazole[4,5â€c]pyridine derivatives as CDK2 inhibitors. Archiv Der Pharmazie, 2018, 351, e1700381.	2.1	7
284	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. , 2018, , 1577-1611.		1
285	Cell Cycle Machinery and Its Alterations in Pancreatic Cancer. , 2018, , 19-49.		2
286	Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor. Chemical Communications, 2018, 54, 4521-4524.	2.2	11
287	SAR study on N²,N⁴-disubstituted pyrimidine-2,4-diamines as effective CDK2/CDK9 inhibitors and antiproliferative agents. RSC Advances, 2018, 8, 11871-11885.	1.7	9
288	miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein. Scientific Reports, 2018, 8, 4482.	1.6	25
289	Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 181-210.	0.1	3
290	Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors. Bioorganic Chemistry, 2018, 79, 46-59.	2.0	55
291	Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/GSK3Î²/cyclin D1 pathway. Journal of Ethnopharmacology, 2018, 210, 1-9.	2.0	77
292	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment, 2018, 167, 659-669.	1.1	64

#	Article	IF	Citations
293	Cyclin D1, Metabolism, and the Autophagy-Senescence Balance. Current Cancer Research, 2018, , 111-131.	0.2	0
294	Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut, 2018, 67, 931-944.	6.1	138
295	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2â^' advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment, 2018, 168, 127-134.	1.1	90
296	The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. Antiviral Research, 2018, 149, 211-220.	1.9	86
297	A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. European Journal of Medicinal Chemistry, 2018, 144, 1-28.	2.6	40
298	Emerging Innovative Therapeutic Approaches Leveraging Cyclinâ€Dependent Kinase Inhibitors to Treat Advanced Breast Cancer. Clinical Pharmacology and Therapeutics, 2018, 103, 1009-1019.	2.3	5
299	Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer. Breast Cancer Research and Treatment, 2018, 168, 287-297.	1.1	30
300	Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Targeted Oncology, 2018, 13, 21-38.	1.7	78
301	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	7.7	503
302	Tetrandrine and cancer â€“ An overview on the molecular approach. Biomedicine and Pharmacotherapy, 2018, 97, 624-632.	2.5	84
303	Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer, 2018, 25, 17-27.	1.3	34
304	Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 354-363.	1.9	14
305	Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest. International Journal of Oncology, 2018, 53, 835-843.	1.4	28
306	Tubeimoside-1, Triterpenoid Saponin, as a Potential Natural Cancer Killer. Natural Product Communications, 2018, 13, 1934578X1801300.	0.2	6
308	Drug repositioning using drug-disease vectors based on an integrated network. BMC Bioinformatics, 2018, 19, 446.	1.2	20
309	Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miRâ€145â€3p on gene regulation. International Journal of Oncology, 2019, 54, 673-688.	1.4	20
310	Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review. New Journal of Chemistry, 2018, 42, 18500-18507.	1.4	32
311	Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. Molecular Medicine Reports, 2018, 18, 3469-3475.	1.1	9

#	Article	IF	Citations
312	Management of Hormone Receptor-Positive Metastatic Breast Cancer. , 0, , .		0
313	Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880850.	1.4	30
314	The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget, 2018, 9, 35226-35240.	0.8	59
315	Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors. Molecules, 2018, 23, 2924.	1.7	9
316	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. Biochemical and Biophysical Research Communications, 2018, 506, 912-917.	1.0	29
317	CDK5 Functions as a Tumor Promoter in Human Lung Cancer. Journal of Cancer, 2018, 9, 3950-3961.	1.2	22
318	Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. Oncotarget, 2018, 9, 22749-22768.	0.8	8
319	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. Npj Breast Cancer, 2018, 4, 38.	2.3	78
320	Promotion of Myoblast Differentiation by Fkbp5 via Cdk4 Isomerization. Cell Reports, 2018, 25, 2537-2551.e8.	2.9	26
321	A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 1249-1270.	1.1	164
322	The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia, 2018, 20, 1121-1134.	2.3	32
323	Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNSâ€'032, on cervical cancer. International Journal of Oncology, 2018, 53, 703-712.	1.4	16
324	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. Journal of Cancer, 2018, 9, 3394-3399.	1.2	5
325	Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm. Cancer Biology and Therapy, 2018, 19, 967-972.	1.5	11
326	T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics. Cell Death and Disease, 2018, 9, 1089.	2.7	60
327	Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell, 2018, 175, 1244-1258.e26.	13.5	182
328	MicroRNAâ€'424 serves an antiâ€'oncogenic role by targeting cyclinâ€'dependent kinaseï¿½1 in breast cancer cells. Oncology Reports, 2018, 40, 3416-3426.	1.2	33
329	Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3736-3740.	1.0	16

#	Article	IF	Citations
330	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion on Emerging Drugs, 2018, 23, 283-299.	1.0	44
331	The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2018, 19, 3219.	1.8	60
332	Online structure-based screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets. Oncotarget, 2018, 9, 32346-32361.	0.8	25
333	Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-car (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. European Journal of Medicinal Chemistry, 2018, 158, 896-916.	2.6	32
334	Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879332.	1.4	104
335	Structural insights into the functional diversity of the CDKâ€“cyclin family. Open Biology, 2018, 8, .	1.5	156
337	An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers. Biomedicine and Pharmacotherapy, 2018, 107, 1326-1341.	2.5	74
338	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open, 2018, 3, e000368.	2.0	35
339	Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Research, 2018, 78, 4360-4369.	0.4	46
341	CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Letters, 2018, 430, 179-192.	3.2	132
342	MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma. European Journal of Endocrinology, 2018, 179, R95-R110.	1.9	25
343	Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells. Bioorganic and Medicinal Chemistry, 2018, 26, 3491-3501.	1.4	26
344	Integrating the DNA damage and protein stress responses during cancer development and treatment. Journal of Pathology, 2018, 246, 12-40.	2.1	79
345	CDK16 overexpressed in non-small cell lung cancer and regulates cancer cell growth and apoptosis via a p27-dependent mechanism. Biomedicine and Pharmacotherapy, 2018, 103, 399-405.	2.5	18
346	The multifaceted allosteric regulation of Aurora kinase A. Biochemical Journal, 2018, 475, 2025-2042.	1.7	44
347	Targeting Cell Cycle Proteins in Brain Cancer. , 2018, , 271-290.		0
348	Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broadâ€spectrum cancer gene therapy - A review of molecular mechanisms for oncologists. Molecular and Clinical Oncology, 2018, 9, 115-134.	0.4	57
349	Clinical and molecular aspects of breast cancer: Targets and therapies. Biomedicine and Pharmacotherapy, 2018, 106, 14-34.	2.5	49

#	Article	IF	Citations
350	Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma. Haematologica, 2018, 103, 2059-2068.	1.7	14
351	Molecular Regulation of Cell Cycle and Cell Cycle-Targeted Therapies in Head and Neck Squamous Cell Carcinoma (HNSCC). Current Cancer Research, 2018, , 185-227.	0.2	0
352	CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner. Cell Cycle, 2018, 17, 1513-1523.	1.3	59
353	TNNT1 facilitates proliferation of breast cancer cells by promoting G1/S phase transition. Life Sciences, 2018, 208, 161-166.	2.0	25
354	Motor neuron and pancreas homeoboxÂ1/HLXB9 promotes sustained proliferation in bladder cancer by upregulating CCNE1/2. Journal of Experimental and Clinical Cancer Research, 2018, 37, 154.	3.5	29
355	Multipronged activity of combinatorial miR-143 and miR-506 inhibits Lung Cancer cell cycle progression and angiogenesis in vitro. Scientific Reports, 2018, 8, 10495.	1.6	25
356	Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity. Bioorganic Chemistry, 2018, 80, 565-576.	2.0	24
357	Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. Endocrine-Related Cancer, 2018, 25, 853-864.	1.6	9
358	Prognostic Value of RNASEH2A-, CDK1-, and CD151-Related Pathway Gene Profiling for Kidney Cancers. International Journal of Molecular Sciences, 2018, 19, 1586.	1.8	8
359	Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. International Journal of Breast Cancer, 2018, 2018, 1-11.	0.6	19
360	<scp>CDK</scp>2 positively regulates aerobic glycolysis by suppressing <scp>SIRT</scp>5 in gastric cancer. Cancer Science, 2018, 109, 2590-2598.	1.7	58
361	Transcriptional analysis of liver from chickens with fast (meat bird), moderate (F1 layer x meat bird) Tj ETQq1 1 0.784314 rgBT /Overlo	1.2	19
362	Betulinic Acid Exerts Cytotoxic Activity Against Multidrug-Resistant Tumor Cells via Targeting Autocrine Motility Factor Receptor (AMFR). Frontiers in Pharmacology, 2018, 9, 481.	1.6	35
363	A perspective on multiâ€target drug discovery and design for complex diseases. Clinical and Translational Medicine, 2018, 7, 3.	1.7	481
364	Cooperative p16 and p21 action protects female astrocytes from transformation. Acta Neuropathologica Communications, 2018, 6, 12.	2.4	47
365	Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease. Frontiers in Endocrinology, 2018, 9, 444.	1.5	7
366	Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 891-900.	1.5	16
367	Recent Advances and Perspectives in Cancer Drug Design. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1233-1250.	0.3	38

#	Article	IF	Citations
368	Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3385-3390.	1.0	9
369	RNAm expression profile of cancer marker genes in HepG2 cells treated with different concentrations of a new indolin-3-one from Pseudomonas aeruginosa. Scientific Reports, 2018, 8, 12781.	1.6	4
370	Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors. European Journal of Medicinal Chemistry, 2018, 157, 935-945.	2.6	10
371	Reassessing the Potential of Myb-targeted Anti-cancer Therapy. Journal of Cancer, 2018, 9, 1259-1266.	1.2	35
372	Recent advances in CDK inhibitors for cancer therapy. Future Medicinal Chemistry, 2018, 10, 1369-1388.	1.1	35
373	Design, synthesis and molecular modeling study of certain 4-Methylbenzenesulfonamides with CDK2 inhibitory activity as anticancer and radio-sensitizing agents. Bioorganic Chemistry, 2018, 80, 276-287.	2.0	15
374	Magnolin promotes autophagy and cell cycle arrest via blocking LIF/Stat3/Mcl-1 axis in human colorectal cancers. Cell Death and Disease, 2018, 9, 702.	2.7	37
375	Cell-Cycle Regulation. , 2018, , 257-269.		3
376	Tau-targeting therapies for Alzheimer disease. Nature Reviews Neurology, 2018, 14, 399-415.	4.9	748
377	Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2019, 25, 403-413.	3.2	56
378	Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment. Journal of Oncology Pharmacy Practice, 2019, 25, 110-129.	0.5	30
379	Stephanthraniline A suppresses proliferation of HCT116 human colon cancer cells through induction of caspase-dependent apoptosis, dysregulation of mitochondrial function, cell cycle arrest and regulation of Akt/p38 signaling pathways. Journal of Toxicological Sciences, 2019, 44, 523-533.	0.7	4
380	PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 790.	1.3	25
381	Potential Anticancer Properties and Mechanisms of Action of Formononetin. BioMed Research International, 2019, 2019, 1-11.	0.9	48
382	Inhibition of UBE2Nâ€dependent CDK6 protein degradation by miRâ€934 promotes human bladder cancer cell growth. FASEB Journal, 2019, 33, 12112-12123.	0.2	18
383	The <scp>TRAPP</scp> complex mediates secretion arrest induced by stress granule assembly. EMBO Journal, 2019, 38, e101704.	3.5	20
384	Predicting the survival of patients with lung adenocarcinoma using a fourâ€gene prognosis risk model. Oncology Letters, 2019, 18, 535-544.	0.8	9
385	Insight into the molecular mechanism of LINC00152/miRâ€215/CDK13 axis in hepatocellular carcinoma progression. Journal of Cellular Biochemistry, 2019, 120, 18816-18825.	1.2	18

#	Article	IF	Citations
386	Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene, 2019, 38, 5905-5920.	2.6	23
387	The Centrosome and the Primary Cilium: The Yin and Yang of a Hybrid Organelle. Cells, 2019, 8, 701.	1.8	70
388	Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Therapeutic Advances in Hematology, 2019, 10, 204062071986064.	1.1	90
389	Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers, 2019, 11, 930.	1.7	8
390	Shrimp miRNA suppresses the stemness of human cancer stem cellsviathe PIN1 pathway. FASEB Journal, 2019, 33, 10767-10779.	0.2	11
391	Regulatory mechanisms and clinical perspectives of circRNA in digestive system neoplasms. Journal of Cancer, 2019, 10, 2885-2891.	1.2	28
392	Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Cell Communication and Signaling, 2019, 17, 85.	2.7	19
393	Curcumol: From Plant Roots to Cancer Roots. International Journal of Biological Sciences, 2019, 15, 1600-1609.	2.6	73
394	Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 514-527.	1.3	5
395	Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids. Frontiers in Oncology, 2019, 9, 487.	1.3	108
396	CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20511-20516.	3.3	17
397	LncRNA LINC00974 Upregulates CDK6 to Promote Cell Cycle Progression in Gastric Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 666-670.	0.7	10
398	Discovery of Dihydropyrrol-2-ones as Novel G0/G1-Phase Arresting Agents Inducing Apoptosis. ACS Omega, 2019, 4, 17556-17560.	1.6	14
399	A Photoaffinity Displacement Assay and Probes to Study the Cyclinâ€Ðependent Kinase Family. Angewandte Chemie - International Edition, 2019, 58, 17322-17327.	7.2	28
400	Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. Biochemical Pharmacology, 2019, 170, 113676.	2.0	64
401	NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor. Cell Reports, 2019, 29, 1469-1481.e9.	2.9	62
402	Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Frontiers in Pharmacology, 2019, 10, 1235.	1.6	24
403	Retrochalcone Echinatin Triggers Apoptosis of Esophageal Squamous Cell Carcinoma via ROS- and ER Stress-Mediated Signaling Pathways. Molecules, 2019, 24, 4055.	1.7	27

#	Article	IF	Citations
404	A Photoaffinity Displacement Assay and Probes to Study the Cyclinâ€Dependent Kinase Family. Angewandte Chemie, 2019, 131, 17483-17488.	1.6	5
405	Identification of Ligandâ€binding Hotspot Residues of CDK4 Using Molecular Docking and Molecular Dynamics Simulation. Bulletin of the Korean Chemical Society, 2019, 40, 1025-1032.	1.0	1
406	P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib. PLoS ONE, 2019, 14, e0223084.	1.1	20
407	Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma. Frontiers in Genetics, 2019, 10, 821.	1.1	28
408	Orientin Induces G0/G1 Cell Cycle Arrest and Mitochondria Mediated Intrinsic Apoptosis in Human Colorectal Carcinoma HT29 Cells. Biomolecules, 2019, 9, 418.	1.8	41
409	The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2â^' Metastatic Breast Cancer: Biological Mechanisms and New Treatments. Cancers, 2019, 11, 1242.	1.7	68
410	Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 2220-2232.	1.9	7
411	eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. Molecular Cancer Therapeutics, 2019, 18, 2158-2170.	1.9	25
412	Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncology, 2019, 15, 3309-3326.	1.1	6
413	Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells, 2019, 8, 1013.	1.8	51
414	Mechanistic insights into the phosphoryl transfer reaction in cyclin-dependent kinase 2: A QM/MM study. PLoS ONE, 2019, 14, e0215793.	1.1	8
415	Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. Journal of Cancer, 2019, 10, 5504-5517.	1.2	60
416	Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. BioDrugs, 2019, 33, 613-620.	2.2	23
417	Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers, 2019, 11, 1433.	1.7	13
418	Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors. Bioorganic Chemistry, 2019, 92, 103239.	2.0	25
419	A Free Web-Based Protocol to Assist Structure-Based Virtual Screening Experiments. International Journal of Molecular Sciences, 2019, 20, 4648.	1.8	16
420	Cyclinâ€'dependent kinase 1 disruption inhibits angiogenesis by inducing cell cycle arrest and apoptosis. Experimental and Therapeutic Medicine, 2019, 18, 3062-3070.	0.8	11
421	New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies. Bioorganic Chemistry, 2019, 86, 80-96.	2.0	59

#	Article	IF	Citations
422	Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Oncogene, 2019, 38, 3355-3370.	2.6	46
423	Aurone: A biologically attractive scaffold as anticancer agent. European Journal of Medicinal Chemistry, 2019, 166, 417-431.	2.6	60
424	Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patientsâ€™ response to cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2019, 135, 21-29.	2.0	23
425	Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinoma. EBioMedicine, 2019, 41, 310-319.	2.7	9
426	CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 125-149.		12
427	Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances. Current Opinion in Obstetrics and Gynecology, 2019, 31, 56-66.	0.9	9
428	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications, 2019, 10, 558.	5.8	76
429	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nature Communications, 2019, 10, 557.	5.8	125
430	Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. Expert Review of Anticancer Therapy, 2019, 19, 569-587.	1.1	21
431	A new small cell lung cancer biomarker identified by Cell-SELEX generated aptamers. Experimental Cell Research, 2019, 382, 111478.	1.2	16
432	The role of cyclinâ€dependent kinases in oral potentially malignant disorders and oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2019, 48, 560-565.	1.4	12
433	Translating RB1 predictive value in clinical cancer therapy: Are we there yet?. Biochemical Pharmacology, 2019, 166, 323-334.	2.0	10
434	Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell Chemical Biology, 2019, 26, 1067-1080.e8.	2.5	151
435	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, 392-398.	1.1	12
436	2â€²,4â€²-Dihydroxy-6â€²-methoxy-3â€²,5â€²-dimethylchalcone induced apoptosis and G1 cell cycle arrest through PI3K/AKT pathway in BEL-7402/5-FU cells. Food and Chemical Toxicology, 2019, 131, 110533.	1.8	19
437	A Marine-based Meriolin (3-Pyrimidinylazaindole) Derivative (4ab) Targets PI3K/AKT /mTOR Pathway Inducing Cell Cycle Arrest and Apoptosis in Molt-4 Cells. Clinical Cancer Drugs, 2019, 6, 33-40.	0.3	5
438	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 2019, 10, 2204.	5.8	69
439	CCNE1 amplification is associated with liver metastasis in gastric carcinoma. Pathology Research and Practice, 2019, 215, 152434.	1.0	22

#	Article	IF	Citations
440	Highlights on Specific Biological Targets; Cyclin-Dependent Kinases, Epidermal Growth Factor Receptors, Ras Protein, and Cancer Stem Cells in Anticancer Drug Development. Drug Research, 2019, 69, 471-478.	0.7	24
441	Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. Trends in Cancer, 2019, 5, 308-324.	3.8	113
442	Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities. European Journal of Medicinal Chemistry, 2019, 177, 32-46.	2.6	31
443	Role of cyclinâ€dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. Hepatology Research, 2019, 49, 1097-1108.	1.8	37
444	CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells. Pharmaceuticals, 2019, 12, 50.	1.7	10
445	Modulation of the cell cycle regulating transcription factor E2F1 pathway by the proteasome following amino acid starvation. Biochemical and Biophysical Research Communications, 2019, 513, 721-725.	1.0	4
446	High Expression of Human AugminComplex Submit 3 Indicates Poor Prognosis and Associates with Tumor Progression in Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 1434-1443.	1.2	12
447	The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation. Drug Resistance Updates, 2019, 43, 29-37.	6.5	33
448	RB constrains lineage fidelity and multiple stages of tumour progression and metastasis. Nature, 2019, 569, 423-427.	13.7	62
449	Overexpression of cyclinâ€dependent kinase 4 protein in extramammary Paget's disease. Journal of Dermatology, 2019, 46, 444-448.	0.6	12
450	Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. Cancer Biomarkers, 2019, 24, 351-361.	0.8	7
451	Targeting Molecular Pathways in Intracranial Metastatic Disease. Frontiers in Oncology, 2019, 9, 99.	1.3	10
452	Discovery of CDK5 Inhibitors through Structure-Guided Approach. ACS Medicinal Chemistry Letters, 2019, 10, 786-791.	1.3	18
453	Safety and efficacy profile of cyclinâ€dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A metaâ€analysis of clinical trials. Cancer Medicine, 2019, 8, 1389-1400.	1.3	12
454	Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs. Molecular Cancer Therapeutics, 2019, 18, 771-779.	1.9	27
455	Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 175, 649-658.	1.1	5
456	Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1375-1379.	1.0	95
457	MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine, 2019, 43, 225-237.	2.7	48

#	Article	IF	Citations
458	Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation. Oncology Reports, 2019, 41, 2667-2678.	1.2	3
459	The synergistic impact of quinacrine on cell cycle and anti-invasiveness behaviors of doxorubicin in MDA-MB-231 breast cancer cells. Process Biochemistry, 2019, 81, 175-181.	1.8	17
460	Development of tau-directed small molecule modulators for Alzheimerâ€™s disease: a recent patent review (2014â€“2018). Pharmaceutical Patent Analyst, 2019, 8, 15-39.	0.4	10
461	Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis. Journal of Visualized Experiments, 2019, , .	0.2	6
462	Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Cells, 2019, 8, 321.	1.8	100
463	Novel dodecyl-containing azido and glucuronamide-based nucleosides exhibiting anticancer potential. Pure and Applied Chemistry, 2019, 91, 1085-1105.	0.9	7
464	Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling. Cancers, 2019, 11, 402.	1.7	31
465	Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway. Cell Death and Disease, 2019, 10, 297.	2.7	40
466	A deep learning model based on sparse auto-encoder for prioritizing cancer-related genes and drug target combinations. Carcinogenesis, 2019, 40, 624-632.	1.3	14
467	Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. European Journal of Medicinal Chemistry, 2019, 172, 143-153.	2.6	72
468	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptorâ€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1169-1178.	0.8	266
469	A Theoretical Model for the Cell Cycle and Drug Induced Cell Cycle Arrest of FUCCI Systems with Cell-to-Cell Variation during Mitosis. Pharmaceutical Research, 2019, 36, 57.	1.7	7
470	CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Current Oncology Reports, 2019, 21, 25.	1.8	122
471	CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target. Cell Cycle, 2019, 18, 452-466.	1.3	10
472	Revealing quinquennial anticancer journey of morpholine: A SAR based review. European Journal of Medicinal Chemistry, 2019, 167, 324-356.	2.6	76
473	E2F is required for STAT3-mediated upregulation of cyclin B1 and Cdc2 expressions and contributes to G2–M phase transition. Acta Biochimica Et Biophysica Sinica, 2019, 51, 313-322.	0.9	19
474	MiR-219-5p suppresses cell proliferation and cell cycle progression in esophageal squamous cell carcinoma by targeting CCNA2. Cellular and Molecular Biology Letters, 2019, 24, 4.	2.7	35
475	Polyomavirus T Antigen InducesAPOBEC3BExpression Using an LXCXE-Dependent and TP53-Independent Mechanism. MBio, 2019, 10, .	1.8	35

#	Article	IF	Citations
476	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. International Journal of Molecular Sciences, 2019, 20, 667.	1.8	19
477	Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers, 2019, 11, 2005.	1.7	10
478	Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer. Scientific Reports, 2019, 9, 17663.	1.6	20
479	Synthesis, Crystal Structure, and Antiproliferative Activity of Novel 7-Arylaminopyrazolo[1,5-a]pyrimidine Derivatives Containing the Hydrazone Moiety. Russian Journal of General Chemistry, 2019, 89, 2321-2327.	0.3	2
480	Genetic determinants of the molecular portraits of epithelial cancers. Nature Communications, 2019, 10, 5666.	5.8	21
481	Surprising regulation of cell cycle entry. Science, 2019, 366, 1315-1316.	6.0	8
482	LncRNA MAGI2-AS3 is involved in cervical squamous cell carcinoma development through CDK6 up-regulation. Infectious Agents and Cancer, 2019, 14, 37.	1.2	22
483	Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: Cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation. Journal of Molecular Structure, 2019, 1176, 538-551.	1.8	38
484	Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptorâ€“Positive/HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, e186-e194.	1.1	27
485	Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine, 2019, 39, 182-193.	2.7	71
486	Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells. European Journal of Pharmacology, 2019, 846, 12-22.	1.7	11
487	Acute myeloid leukemia with eosinophilia after cyclinâ€dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. American Journal of Hematology, 2019, 94, E82-E85.	2.0	2
488	Furowanin A-induced autophagy alleviates apoptosis and promotes cell cycle arrest via inactivation STAT3/Mcl-1 axis in colorectal cancer. Life Sciences, 2019, 218, 47-57.	2.0	10
489	Downregulation of EIF5A2 by miR-221-3p inhibits cell proliferation, promotes cell cycle arrest and apoptosis in medulloblastoma cells. Bioscience, Biotechnology and Biochemistry, 2019, 83, 400-408.	0.6	27
490	MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1). Biomedicine and Pharmacotherapy, 2019, 111, 517-526.	2.5	33
491	CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. European Journal of Medicinal Chemistry, 2019, 164, 77-91.	2.6	49
492	CtIP promotes G2/M arrest in etoposideâ€treated HCT116 cells in a p53â€independent manner. Journal of Cellular Physiology, 2019, 234, 11871-11881.	2.0	6
493	Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription, 2019, 10, 118-136.	1.7	78

#	Article	IF	Citations
494	THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism. Acta Pharmacologica Sinica, 2019, 40, 814-822.	2.8	31
495	Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer. Cell Death and Differentiation, 2019, 26, 1442-1452.	5.0	35
496	Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chemical Biology, 2019, 26, 121-130.e5.	2.5	72
497	It takes a team: a gain-of-function story of p53-R249S. Journal of Molecular Cell Biology, 2019, 11, 277-283.	1.5	27
498	1,2,4-Triazolo[1,5-a]pyrimidines in drug design. European Journal of Medicinal Chemistry, 2019, 165, 332-346.	2.6	68
499	Tau PET imaging in neurodegenerative tauopathiesâ€"still a challenge. Molecular Psychiatry, 2019, 24, 1112-1134.	4.1	409
500	An <scp>TRIM</scp>59â€«<scp>CDK</scp>6 axis regulates growth and metastasis of lung cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 1458-1469.	1.6	18
501	An in silico approach to discover the best molecular modeling strategy for designing novelCDK4 inhibitors. Chemical Biology and Drug Design, 2019, 93, 556-569.	1.5	2
502	Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. Journal of Medicinal Chemistry, 2019, 62, 4233-4251.	2.9	162
503	Resveratrol analog, N-(4-methoxyphenyl)-3,5-dimethoxybenzamide induces G2/M phase cell cycle arrest and apoptosis in HeLa human cervical cancer cells. Food and Chemical Toxicology, 2019, 124, 101-111.	1.8	11
504	Long non-coding RNA DLEU1 exerts an oncogenic function in non-small cell lung cancer. Biomedicine and Pharmacotherapy, 2019, 109, 985-990.	2.5	20
505	Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development. Molecular and Cellular Proteomics, 2019, 18, 437-447.	2.5	22
506	Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacological Research, 2019, 139, 471-488.	3.1	270
507	Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimerâ€™s disease. Journal of Biomolecular Structure and Dynamics, 2020, 38, 248-262.	2.0	37
508	Psoriatic epidermis is associated with upregulation of <scp>CDK</scp> 2 and inhibition of <scp>CDK</scp> 4 activity. British Journal of Dermatology, 2020, 182, 678-689.	1.4	24
509	Control of the Cell Cycle. , 2020, , 56-73.e5.		1
510	To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response. DNA Repair, 2020, 85, 102702.	1.3	25
511	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma. Haematologica, 2020, 105, 1021-1031.	1.7	6

#	Article	IF	Citations
512	Development and strategies of CDK4/6 inhibitors. Future Medicinal Chemistry, 2020, 12, 127-145.	1.1	7
513	Heterobinuclear copper(II)â€˜platinum(II) complexes with oxindolimine ligands: Interactions with DNA, and inhibition of kinase and alkaline phosphatase proteins. Journal of Inorganic Biochemistry, 2020, 203, 110863.	1.5	4
514	Inhibition of the ATRâ€“CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. Molecular Cancer Research, 2020, 18, 91-104.	1.5	43
515	CDK4/6 inhibitors in breast cancer â€“ frominÂvitromodels to clinical trials. Acta OncolÃ³gica, 2020, 59, 219-232.	0.8	8
516	Evaluation of the pharmacokinetics of the simultaneous quantification of letrozole and palbociclib in rat plasma by a developed and validated HPLCâ€“PDA. Acta Chromatographica, 2020, 32, 170-178.	0.7	4
517	Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, 117-124.e4.	1.1	3
518	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-NaÃ¯ve Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 110-121.	3.2	120
519	The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death. Cancers, 2020, 12, 108.	1.7	14
520	Depletion of CDC5L inhibits bladder cancer tumorigenesis. Journal of Cancer, 2020, 11, 353-363.	1.2	25
521	Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 414-423.	2.5	19
522	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 2020, 37, 37-54.e9.	7.7	138
523	CDK9 inhibitors reactivate p53 by downregulating iASPP. Cellular Signalling, 2020, 67, 109508.	1.7	18
524	AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. Clinical Cancer Research, 2020, 26, 922-934.	3.2	165
525	Development of selective mono or dual PROTAC degrader probe of CDK isoforms. European Journal of Medicinal Chemistry, 2020, 187, 111952.	2.6	71
526	ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. Cell Death and Differentiation, 2020, 27, 1981-1997.	5.0	30
527	Reactivation of Endogenous Retroelements in Cancer Development and Therapy. Annual Review of Cancer Biology, 2020, 4, 159-176.	2.3	36
528	Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells. Cancer Biology and Therapy, 2020, 21, 269-277.	1.5	10
529	A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor. Molecules, 2020, 25, 4400.	1.7	25

#	Article	IF	Citations
530	Developing themes in targeted therapies for hormone receptorâ€“positive breast cancer. Current Opinion in Endocrine and Metabolic Research, 2020, 15, 15-23.	0.6	0
531	Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. Cancer Treatment Reviews, 2020, 90, 102086.	3.4	29
532	Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor. European Journal of Medicinal Chemistry, 2020, 208, 112770.	2.6	27
533	Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer. Cancer Biology and Therapy, 2020, 21, 994-1004.	1.5	7
534	Mitotic Poisons in Research and Medicine. Molecules, 2020, 25, 4632.	1.7	25
535	Aldose reductase inhibitor form Cassia glauca: A comparative study of cytotoxic activity with Ag nanoparticles (NPs) and molecular docking evaluation. PLoS ONE, 2020, 15, e0240856.	1.1	5
536	Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis. Technology in Cancer Research and Treatment, 2020, 19, 153303382096213.	0.8	6
537	Cyclin K interacts with Î²-catenin to induce Cyclin D1 expression and facilitates tumorigenesis and radioresistance in lung cancer. Theranostics, 2020, 10, 11144-11158.	4.6	14
538	Phosphoprotein-based biomarkers as predictors for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18401-18411.	3.3	25
539	MASTL: A novel therapeutic target for Cancer Malignancy. Cancer Medicine, 2020, 9, 6322-6329.	1.3	18
540	The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2â^' Breast Cancer. Cells, 2020, 9, 1643.	1.8	76
541	Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment. Cell Reports, 2020, 32, 107884.	2.9	19
542	Getting under the skin: The role of CDK4/6 in melanomas. European Journal of Medicinal Chemistry, 2020, 204, 112531.	2.6	19
543	Discovery of 12Oâ€"A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor. Molecules, 2020, 25, 5199.	1.7	3
544	Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets. Npj Precision Oncology, 2020, 4, 31.	2.3	19
545	Resistance and Overcoming Resistance in Breast Cancer . Breast Cancer: Targets and Therapy, 2020, Volume 12, 211-229.	1.0	50
546	Synthesis, Crystal Structure and Biological Activity of 7-(4-Methylpiperazin-1-Yl)-5-[4-(Trifluoromethyl)Phenyl]pyrazolo[1,5-a]Pyrimidine-3-Carbonitrile. Crystallography Reports, 2020, 65, 1111-1116.	0.1	1
547	Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. Frontiers in Pharmacology, 2020, 11, 580251.	1.6	38

#	Article	IF	Citations
548	Bioinformatics Analysis and Validation Identify CDK1 and MAD2L1 as Prognostic Markers of Rhabdomyosarcoma . Cancer Management and Research, 2020, Volume 12, 12123-12136.	0.9	10
549	Restricted suitability of BODIPY for caging in biological applications based on singlet oxygen generation. Photochemical and Photobiological Sciences, 2020, 19, 1319-1325.	1.6	7
550	MAPRE1 promotes cell cycle progression of hepatocellular carcinoma cells by interacting with CDK2. Cell Biology International, 2020, 44, 2326-2333.	1.4	11
551	Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1616-1630.	2.5	42
552	Restriction point regulation at the crossroads between quiescence and cell proliferation. FEBS Letters, 2020, 594, 2046-2060.	1.3	52
553	Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening. Future Medicinal Chemistry, 2020, 12, 1121-1136.	1.1	9
554	Regional Variation in Epidermal Susceptibility to UV-Induced Carcinogenesis Reflects Proliferative Activity of Epidermal Progenitors. Cell Reports, 2020, 31, 107702.	2.9	9
555	Biological activities of [1,2,4]triazolo[1,5-a]pyrimidines and analogs. Medicinal Chemistry Research, 2020, 29, 1751-1776.	1.1	20
556	Tumor-specific genetic profiling and therapy in biomedicine. , 2020, , 459-485.		0
557	Synergistic drug combinations and machine learning for drug repurposing in chordoma. Scientific Reports, 2020, 10, 12982.	1.6	27
558	Clinical significance of p27 Kip1 expression in advanced ovarian cancer. Applied Cancer Research, 2020, 40, .	1.0	3
559	One drug to treat many diseases: unlocking the economic trap of rare diseases. Metabolic Brain Disease, 2020, 35, 1237-1240.	1.4	8
560	Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Scientific Reports, 2020, 10, 18489.	1.6	41
561	Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry. Journal of Medicinal Chemistry, 2020, 63, 14243-14275.	2.9	184
562	Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. Journal of Hematology and Oncology, 2020, 13, 118.	6.9	95
563	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. International Journal of Molecular Sciences, 2020, 21, 6350.	1.8	34
564	Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 â€“ 2019). Expert Opinion on Therapeutic Patents, 2020, 30, 795-805.	2.4	7
565	Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation. Frontiers in Chemistry, 2020, 8, 691.	1.8	9

#	Article	IF	Citations
566	FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells. Cancers, 2020, 12, 2655.	1.7	16
567	Androgen Receptor in Breast Cancer: From Bench to Bedside. Frontiers in Endocrinology, 2020, 11, 573.	1.5	31
568	Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. Journal of Medicinal Chemistry, 2020, 63, 13228-13257.	2.9	54
569	CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge. Cancers, 2020, 12, 2480.	1.7	15
570	Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. International Journal of Molecular Sciences, 2020, 21, 6479.	1.8	71
571	The Molecular â€˜Myc-anismsâ€™ behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics. International Journal of Molecular Sciences, 2020, 21, 9486.	1.8	15
572	Centrosomal Localization of RXRÎ± Promotes PLK1 Activation and Mitotic Progression and Constitutes a Tumor Vulnerability. Developmental Cell, 2020, 55, 707-722.e9.	3.1	6
573	Palbociclib in the treatment of recurrent ovarian cancer. Gynecologic Oncology Reports, 2020, 34, 100626.	0.3	6
574	Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. Journal of Hematology and Oncology, 2020, 13, 170.	6.9	25
575	Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1Î± and beclin1 in Breast Cancer Patients. Journal of Investigative Surgery, 2022, 35, 442-447.	0.6	8
576	Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis. Bioorganic Chemistry, 2020, 104, 104345.	2.0	15
577	Identification of small molecules against cyclin dependent kinase-5 using chemoinformatics approach for Alzheimerâ€™s disease and other tauopathies. Journal of Biomolecular Structure and Dynamics, 2022, 40, 2815-2827.	2.0	10
578	A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 2516-2527.	1.9	17
579	Oncogenic action of the exosome cofactor RBM7 by stabilization of CDK1 mRNA in breast cancer. Npj Breast Cancer, 2020, 6, 58.	2.3	18
580	The application and prospect of CDK4/6 inhibitors in malignant solid tumors. Journal of Hematology and Oncology, 2020, 13, 41.	6.9	91
581	Inhibition of PI3K/AKT molecular pathway mediated by membrane estrogen receptor GPER accounts for cryptotanshinone induced antiproliferative effect on breast cancer SKBR-3 cells. BMC Pharmacology & Toxicology, 2020, 21, 32.	1.0	18
582	Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindoleâ€“Indole Conjugates as Anticancer CDK Inhibitors. Molecules, 2020, 25, 2031.	1.7	35
583	Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?. Current Oncology Reports, 2020, 22, 57.	1.8	26

#	Article	IF	Citations
584	Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 115-126.	1.8	16
585	Therapy after cyclinâ€dependent kinase inhibition in metastatic hormone receptorâ€positive breast cancer: Resistance mechanisms and novel treatment strategies. Cancer, 2020, 126, 3400-3416.	2.0	19
586	CDK7 inhibitors as anticancer drugs. Cancer and Metastasis Reviews, 2020, 39, 805-823.	2.7	101
587	Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms. Experimental and Molecular Medicine, 2020, 52, 713-723.	3.2	44
588	CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. Diagnostics, 2020, 10, 279.	1.3	59
589	The dormant cancer cell life cycle. Nature Reviews Cancer, 2020, 20, 398-411.	12.8	286
590	Quantifying CDK inhibitor selectivity in live cells. Nature Communications, 2020, 11, 2743.	5.8	64
591	Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery. International Journal of Molecular Sciences, 2020, 21, 3354.	1.8	32
592	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. Genomics, Proteomics and Bioinformatics, 2020, 18, 26-40.	3.0	14
593	Function, Structure and Topology of Protein Kinases. Topics in Medicinal Chemistry, 2020, , 1-24.	0.4	4
594	Identification of co-expression modules and potential biomarkers of breast cancer by WGCNA. Gene, 2020, 750, 144757.	1.0	36
595	1-(3-Amino-4-morpholino-1H-indazole-1-carbonyl)-N-phenylcyclopropane-1-carboxamide: Design, synthesis, crystal structure, antitumor activity, DFT and Hirshfeld surface analysis. Journal of Molecular Structure, 2020, 1210, 127996.	1.8	9
596	Senescence as a therapeutically relevant response to CDK4/6 inhibitors. Oncogene, 2020, 39, 5165-5176.	2.6	73
597	Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. Journal of Medicinal Chemistry, 2020, 63, 6708-6726.	2.9	23
598	CDK12: A Potent Target and Biomarker for Human Cancer Therapy. Cells, 2020, 9, 1483.	1.8	37
599	Discovering and validating cancer genetic dependencies: approaches and pitfalls. Nature Reviews Genetics, 2020, 21, 671-682.	7.7	41
600	Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2305-2317.	2.0	11
601	HOTAIRâ€EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma. Clinical and Translational Medicine, 2020, 10, 182-198.	1.7	18

#	Article	IF	Citations
602	Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Frontiers in Chemistry, 2020, 8, 147.	1.8	12
603	A Comprehensive Review on Schisandrin B and Its Biological Properties. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	1.9	64
604	Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives . Breast Cancer: Targets and Therapy, 2020, Volume 12, 45-56.	1.0	15
605	The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1960.	1.8	270
606	CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?. Journal of Medicinal Chemistry, 2020, 63, 7458-7474.	2.9	42
607	Transcription and Translation Inhibitors in Cancer Treatment. Frontiers in Chemistry, 2020, 8, 276.	1.8	54
608	CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nature Communications, 2020, 11, 1557.	5.8	38
609	Clinico-pathological significance of Drp1 dysregulation and its correlation to apoptosis in oral cancer patients. Mitochondrion, 2020, 52, 115-124.	1.6	4
610	Cyclin-dependent kinase inhibitors for the treatment of lung cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 941-952.	0.9	19
611	Discovery and SARs of 5-Chloro-<i>N</i>⁴-phenyl-<i>N</i>²-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity. Journal of Medicinal Chemistry, 2020, 63, 3327-3347.	2.9	15
612	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet, The, 2020, 395, 817-827.	6.3	260
613	Oleandrin: A bioactive phytochemical and potential cancer killer via multiple cellular signaling pathways. Food and Chemical Toxicology, 2020, 143, 111570.	1.8	34
614	Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer. Cancers, 2020, 12, 306.	1.7	19
615	Cell cycle regulators in cancer cell metabolism. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165715.	1.8	110
616	Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. Theranostics, 2020, 10, 2008-2028.	4.6	15
617	CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell, 2020, 37, 340-353.e6.	7.7	114
618	A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib. Pharmacological Research, 2020, 156, 104686.	3.1	61
619	Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discovery, 2020, 10, 351-370.	7.7	162

#	Article	IF	Citations
620	Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options . Cancer Management and Research, 2020, Volume 12, 675-686.	0.9	27
621	The role of B-Cell Lymphoma-3 (BCL-3) in enabling the hallmarks of cancer: implications for the treatment of colorectal carcinogenesis. Carcinogenesis, 2020, 41, 249-256.	1.3	19
622	Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant. Journal of Physical Education and Sports Management, 2020, 6, a004713.	0.5	5
623	Synthesis of AIE-Active Materials with Their Applications for Antibacterial Activity, Specific Imaging of Mitochondrion and Image-Guided Photodynamic Therapy. ACS Applied Bio Materials, 2020, 3, 1187-1196.	2.3	24
624	Binding patterns and structureâ€“activity relationship of CDK8 inhibitors. Bioorganic Chemistry, 2020, 96, 103624.	2.0	6
625	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent inÂvitro and inÂvivo anticancer activity. European Journal of Medicinal Chemistry, 2020, 189, 112073.	2.6	25
626	Down-regulation of CIT can inhibit the growth of human bladder cancer cells. Biomedicine and Pharmacotherapy, 2020, 124, 109830.	2.5	10
627	Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis. Translational Cancer Research, 2020, 9, 657-668.	0.4	3
628	CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 3018.	1.8	30
629	Is there a CDKN2A-centric networkÂinÂpancreatic ductal adenocarcinoma? . OncoTargets and Therapy, 2020, Volume 13, 2551-2562.	1.0	11
630	Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms. Biochemical Pharmacology, 2020, 177, 113939.	2.0	17
631	Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. Cancer Cell, 2020, 37, 514-529.	7.7	201
632	Cardamonin: A new player to fight cancer via multiple cancer signaling pathways. Life Sciences, 2020, 250, 117591.	2.0	56
633	Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. Frontiers in Genetics, 2020, 11, 349.	1.1	9
634	A rapid and sensitive bioanalytical LCâ€“MS/MS method for the quantitation of a novel CDK5 inhibitor 20â€“223 (CP668863) in plasma: Application to in vitro metabolism and plasma proteinâ€binding studies. Biomedical Chromatography, 2020, 34, e4859.	0.8	5
635	Pan-cancer molecular analysis of the RB tumor suppressor pathway. Communications Biology, 2020, 3, 158.	2.0	50
636	Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer. European Journal of Medicinal Chemistry, 2020, 198, 112322.	2.6	15
637	G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 2921.	1.8	100

#	Article	IF	Citations
638	Mammalian cell cycle cyclins. Seminars in Cell and Developmental Biology, 2020, 107, 28-35.	2.3	81
639	Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. Oncogene, 2020, 39, 4781-4797.	2.6	52
640	Bidirectional Regulation between NDRG1 and GSK3Î² Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma. Cancer Research, 2020, 80, 234-248.	0.4	20
641	Cyclin-dependent kinase 7 inhibitors in cancer therapy. Future Medicinal Chemistry, 2020, 12, 813-833.	1.1	11
642	Small-molecule PROTACs: novel agents for cancer therapy. Future Medicinal Chemistry, 2020, 12, 915-938.	1.1	19
643	Phytochemical Profile, and Antiproliferative and Proapoptotic Effects of Pouteria ramiflora (Mart.) Radlk. Leaf Extract, and Its Synergism with Cisplatin in HepG2 Cells. Journal of Medicinal Food, 2021, 24, 452-463.	0.8	1
644	First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 inÂvivo. European Journal of Medicinal Chemistry, 2021, 209, 112903.	2.6	57
645	Phosphorylation regulates cullin-based ubiquitination in tumorigenesis. Acta Pharmaceutica Sinica B, 2021, 11, 309-321.	5.7	29
646	Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2021, 22, 351-361.	0.9	10
647	CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycleâ€“Dependent Degradation of CDK2. SLAS Discovery, 2021, 26, 560-569.	1.4	21
648	Systematic Identification of Molecular Targets and Pathways Related to Human Organ Level Toxicity. Chemical Research in Toxicology, 2021, 34, 412-421.	1.7	16
649	CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy, 2021, 21, 283-298.	1.1	39
650	Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert Opinion on Investigational Drugs, 2021, 30, 61-76.	1.9	7
651	An evaluation of palbociclib as a breast cancer treatment option: a current update. Expert Opinion on Pharmacotherapy, 2021, 22, 281-290.	0.9	3
652	How selective are clinical CDK4/6 inhibitors?. Medicinal Research Reviews, 2021, 41, 1578-1598.	5.0	15
653	How a Second Mg²⁺ Ion Affects the Phosphoryl-Transfer Mechanism in a Protein Kinase: A Computational Study. ACS Catalysis, 2021, 11, 169-183.	5.5	7
654	Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition. Cancer Research, 2021, 81, 1347-1360.	0.4	40
655	Preclinical discovery and development of abemaciclib used to treat breast cancer. Expert Opinion on Drug Discovery, 2021, 16, 485-496.	2.5	6

#	Article	IF	Citations
656	Partial Inhibition of Mitochondrial Complex I Reduces Tau Pathology and Improves Energy Homeostasis and Synaptic Function in 3xTg-AD Mice. Journal of Alzheimer's Disease, 2021, 79, 335-353.	1.2	22
657	Novel Cu2+ and Zn2+ nanocomplexes drug based on hydrazone ligand bearings chromone and triazine moieties: Structural, spectral, DFT, molecular docking and cytotoxic studies. Journal of Molecular Structure, 2021, 1225, 129158.	1.8	24
658	Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 15-33.	2.5	25
659	Integrating proteomics into precision oncology. International Journal of Cancer, 2021, 148, 1438-1451.	2.3	15
660	Nanobiosensor Reports on CDK1 Kinase Activity in Tumor Xenografts in Mice. Small, 2021, 17, 2007177.	5.2	4
662	Study of cytostatic and cytotoxic characteristics of modified peptide CDK4/6 inhibitors â€“ functional analogs of p16INK4a (90-97). Uspehi Molekularnoj Onkologii, 2021, 7, 37-45.	0.1	0
663	Loss of Mediator complex subunit 13 (MED13) promotes resistance to alkylation through cyclin D1 upregulation. Nucleic Acids Research, 2021, 49, 1470-1484.	6.5	1
664	Medicinal attributes of pyridine scaffold as anticancer targeting agents. Future Journal of Pharmaceutical Sciences, 2021, 7, .	1.1	34
665	Toward Identifying Key Gene Group in the Occurrence and Development of Lung Adenocarcinoma. IEEE Access, 2021, 9, 26156-26167.	2.6	0
666	Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis. Journal of Cancer, 2021, 12, 3539-3547.	1.2	4
667	Combination therapies for MPNSTs targeting RABL6A-RB1 signaling. Oncotarget, 2021, 12, 10-14.	0.8	5
668	Inversion kinetics of some E/Z 3-(benzylidene)-2-oxo-indoline derivatives and their in silico CDK2 docking studies. RSC Advances, 2021, 11, 7839-7850.	1.7	8
669	Novel Hybrid CHC from Î²-carboline and N-Hydroxyacrylamide Overcomes Drug-Resistant Hepatocellular Carcinoma by Promoting Apoptosis, DNA Damage, and Cell Cycle Arrest. Frontiers in Pharmacology, 2020, 11, 626065.	1.6	6
670	Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges. Expert Reviews in Molecular Medicine, 2021, 23, e6.	1.6	10
671	Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines. Biomedicines, 2021, 9, 92.	1.4	41
672	Curcuma and Breast Cancer: A Focus on Cell Signaling Pathways. Food Bioactive Ingredients, 2021, , 179-200.	0.3	1
673	LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. International Journal of Medical Sciences, 2021, 18, 1456-1464.	1.1	19
674	Combination of miRâ€'143 and miRâ€'506 reduces lung and pancreatic cancer cell growth through the downregulation of cyclinâ€'dependent kinases. Oncology Reports, 2021, 45, .	1.2	7

#	Article	IF	Citations
675	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 636.	1.8	29
676	Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharmaceutica Sinica B, 2021, 11, 30-54.	5.7	66
677	Fluorescent Peptide Biosensors for Probing CDK Kinase Activity in Cell Extracts. Methods in Molecular Biology, 2021, 2329, 39-50.	0.4	3
678	Inhibitor of Multi-cyclin-dependent Kinases (AT7519) Reduced Survival of U937 Leukemic Cells and Enhanced Anti-leukemic Effect of Vincristine: A Highlight to CDK Inhibition Efficacy in Acute Leukemia. International Journal of Cancer Management, 2021, 14, .	0.2	0
679	Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma. Molecular Medicine, 2021, 27, 15.	1.9	10
681	DriverSubNet: A Novel Algorithm for Identifying Cancer Driver Genes by Subnetwork Enrichment Analysis. Frontiers in Genetics, 2020, 11, 607798.	1.1	5
682	miR-378a-5p inhibits the proliferation of colorectal cancer cells by downregulating CDK1. World Journal of Surgical Oncology, 2021, 19, 54.	0.8	12
683	Clinical Candidates Targeting the ATRâ€“CHK1â€“WEE1 Axis in Cancer. Cancers, 2021, 13, 795.	1.7	50
684	A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy. Translational Andrology and Urology, 2021, 10, 954-962.	0.6	5
685	The Role of Intrinsic Signaling Pathways in Cell Proliferation. Nano LIFE, 2021, 11, 2030003.	0.6	3
687	Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies. Current Topics in Medicinal Chemistry, 2021, 21, 404-425.	1.0	4
688	Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer. Cancers, 2021, 13, 1135.	1.7	8
689	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2â€positive breast cancer. European Journal of Clinical Investigation, 2021, 51, e13535.	1.7	14
690	Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck. Cancers, 2021, 13, 1251.	1.7	5
691	Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma. Cancers, 2021, 13, 1104.	1.7	8
692	Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors. Bioorganic Chemistry, 2021, 108, 104615.	2.0	27
693	Expression of cyclin-dependent kinases and their clinical significance with immune infiltrates could predict prognosis in colorectal cancer. Biotechnology Reports (Amsterdam, Netherlands), 2021, 29, e00602.	2.1	10
694	Combinatorial mathematical modelling approaches to interrogate rear retraction dynamics in 3D cell migration. PLoS Computational Biology, 2021, 17, e1008213.	1.5	5

#	Article	IF	Citations
695	Development of CDK4/6 Inhibitors: A Five Years Update. Molecules, 2021, 26, 1488.	1.7	17
696	CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism. Frontiers in Cell and Developmental Biology, 2021, 9, 641271.	1.8	11
697	Ocular Toxicity of Targeted Anticancer Agents. Drugs, 2021, 81, 771-823.	4.9	22
698	Steroid Hormone Receptors: Links With Cell Cycle Machinery and Breast Cancer Progression. Frontiers in Oncology, 2021, 11, 620214.	1.3	24
699	CRL4AMBRA1 is a master regulator of D-type cyclins. Nature, 2021, 592, 789-793.	13.7	78
700	Identification of Ten Core Hub Genes as Potential Biomarkers and Treatment Target for Hepatoblastoma. Frontiers in Oncology, 2021, 11, 591507.	1.3	8
701	Knockdown of AURKA sensitizes the efficacy of radiation in human colorectal cancer. Life Sciences, 2021, 271, 119148.	2.0	7
702	Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies. Antiviral Research, 2021, 188, 105034.	1.9	37
703	Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure. European Journal of Medicinal Chemistry, 2021, 216, 113309.	2.6	6
704	Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 4012-4024.	3.2	20
705	Discovery of New Coumarin-Based Lead with Potential Anticancer, CDK4 Inhibition and Selective Radiotheranostic Effect: Synthesis, 2D & 3D QSAR, Molecular Dynamics, In Vitro Cytotoxicity, Radioiodination, and Biodistribution Studies. Molecules, 2021, 26, 2273.	1.7	13
706	Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 511-526.	1.4	3
707	A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomarker Research, 2021, 9, 24.	2.8	14
708	CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated With Better Patient Outcome. Frontiers in Genetics, 2021, 12, 616110.	1.1	2
709	GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration. Oncology Reports, 2021, 45, .	1.2	9
710	Coiled-Coil Domain-Containing 68 Downregulation Promotes Colorectal Cancer Cell Growth by Inhibiting ITCH-Mediated CDK4 Degradation. Frontiers in Oncology, 2021, 11, 668743.	1.3	11
711	A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Science Advances, 2021, 7, .	4.7	15
712	uc.77- Downregulation Promotes Colorectal Cancer Cell Proliferation by Inhibiting FBXW8-Mediated CDK4 Protein Degradation. Frontiers in Oncology, 2021, 11, 673223.	1.3	10

#	Article	IF	Citations
713	Chondrosarcoma-from Molecular Pathology to Novel Therapies. Cancers, 2021, 13, 2390.	1.7	31
714	Glucocappasalin Induces G2/M-Phase Arrest, Apoptosis, and Autophagy Pathways by Targeting CDK1 and PLK1 in Cervical Carcinoma Cells. Frontiers in Pharmacology, 2021, 12, 671138.	1.6	8
715	The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cellsâ€"A Systematic Analysis. Cancers, 2021, 13, 2396.	1.7	6
716	Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1. Aging, 2021, 13, 20094-20115.	1.4	16
717	Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer. Journal of Personalized Medicine, 2021, 11, 407.	1.1	3
719	Clinical significance of CCNE1 copy number gain in acral melanoma patients. Melanoma Research, 2021, Publish Ahead of Print, 352-357.	0.6	1
720	Overview of Ca2+ signaling in lung cancer progression and metastatic lung cancer with bone metastasis. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	2
721	CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. Cells, 2021, 10, 1334.	1.8	31
722	CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Frontiers in Oncology, 2021, 11, 678559.	1.3	62
723	Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations. Bioorganic Chemistry, 2021, 110, 104748.	2.0	50
724	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 201.	7.1	607
725	Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer. DNA Repair, 2021, 102, 103103.	1.3	11
727	Cell cycle regulation by complex nanomachines. FEBS Journal, 2022, 289, 5100-5120.	2.2	11
728	Hypoxia-inducible lipid droplet-associated (HILPDA) facilitates the malignant phenotype of lung adenocarcinoma cells in vitro through modulating cell cycle pathways. Tissue and Cell, 2021, 70, 101495.	1.0	2
729	PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer. Molecular Cancer Therapeutics, 2021, 20, 1680-1691.	1.9	22
730	Targeting cell-cycle machinery in cancer. Cancer Cell, 2021, 39, 759-778.	7.7	207
731	Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma. Aging, 2021, 13, 16425-16444.	1.4	10
732	Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERÎ±) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer. Cancers, 2021, 13, 2799.	1.7	33

#	Article	IF	Citations
733	CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. PLoS ONE, 2021, 16, e0252927.	1.1	3
734	Efficient Synthesis and Docking Analysis of Selective CDK9 Inhibitor NVP-2. Pharmaceutical Fronts, 2021, 03, e50-e55.	0.4	0
735	Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors. European Journal of Medicinal Chemistry, 2021, 218, 113389.	2.6	23
736	CDK6 Is a Therapeutic Target in Myelofibrosis. Cancer Research, 2021, 81, 4332-4345.	0.4	11
737	Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy. Pharmaceuticals, 2021, 14, 648.	1.7	6
738	Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring. Cancer Letters, 2021, 510, 79-92.	3.2	16
739	Bisphenol B stimulates Leydig cell proliferation but inhibits maturation in late pubertal rats. Food and Chemical Toxicology, 2021, 153, 112248.	1.8	8
740	Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. Frontiers in Oncology, 2021, 11, 693104.	1.3	67
741	Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. Journal of Medicinal Chemistry, 2021, 64, 11651-11674.	2.9	33
742	Post-translational modifications of CDK5 and their biological roles in cancer. Molecular Biomedicine, 2021, 2, 22.	1.7	5
743	Design, synthesis, and primary activity assays of baicalein derivatives as cyclinâ€dependent kinase 1 inhibitors. Chemical Biology and Drug Design, 2021, 98, 639-654.	1.5	3
744	Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma. Frontiers in Pharmacology, 2021, 12, 691769.	1.6	5
745	Protein Kinase Inhibitors - Selectivity or Toxicity?. Biochemistry, 0, , .	0.8	3
746	Chemopreventive effects of pterostilbene through p53 and cell cycle in mouse lung of squamous cell carcinoma model. Scientific Reports, 2021, 11, 14862.	1.6	10
747	Advances of Targeted Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 719896.	1.3	23
748	CDK4: A Novel Therapeutic Target for Extramammary Pagetâ€™s Disease. Frontiers in Oncology, 2021, 11, 710378.	1.3	4
749	DSN1 is a prognostic biomarker and correlated with clinical characterize in breast cancer. International Immunopharmacology, 2021, 101, 107605.	1.7	2
750	Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment. Molecules, 2021, 26, 4462.	1.7	22

#	Article	IF	Citations
751	A Genome-Scale CRISPR Knock-Out Screen Identifies MicroRNA-5197-5p as a Promising Radiosensitive Biomarker in Colorectal Cancer. Frontiers in Oncology, 2021, 11, 696713.	1.3	2
752	Photopharmacological Applications for Cherenkov Radiation Generated by Clinically Used Radionuclides. International Journal of Molecular Sciences, 2021, 22, 9010.	1.8	4
753	Integrated analysis of cell cycle-related genes in HR+/HER2â^' breast cancer. Breast Cancer, 2021, , 1.	1.3	1
754	The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy. Current Medicinal Chemistry, 2022, 29, 1891-1919.	1.2	7
755	Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death and Disease, 2021, 12, 763.	2.7	8
756	Trends in kinase drug discovery: targets, indications and inhibitor design. Nature Reviews Drug Discovery, 2021, 20, 839-861.	21.5	340
757	4-Hydroxyderricin Promotes Apoptosis and Cell Cycle Arrest through Regulating PI3K/AKT/mTOR Pathway in Hepatocellular Cells. Foods, 2021, 10, 2036.	1.9	11
758	Chrysosplenol D Triggers Apoptosis through Heme Oxygenase-1 and Mitogen-Activated Protein Kinase Signaling in Oral Squamous Cell Carcinoma. Cancers, 2021, 13, 4327.	1.7	10
759	CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy. International Journal of Molecular Sciences, 2021, 22, 8391.	1.8	17
760	Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSÃ©-ESMART Trial. Journal of Clinical Oncology, 2021, 39, 3546-3560.	0.8	17
761	Basic Pan-Cancer Analysis of the Carcinogenic Effects of Cyclin-Dependent Kinase 4 (CDK4) in Human Surface Tumors. Journal of Healthcare Engineering, 2021, 2021, 1-14.	1.1	0
762	Role of Bclaf1 in Promoting Adrenocortical Carcinoma Proliferation: A Study Combining the Use of Bioinformatics and Molecular Events. Cancer Management and Research, 2021, Volume 13, 6785-6795.	0.9	3
763	Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. Clinical and Translational Oncology, 2022, 24, 161-192.	1.2	31
764	Hydrogen Evolution from Telescoped Miyaura Borylation and Suzuki Couplings Utilizing Diboron Reagents: Process Safety and Hazard Considerations. Organic Process Research and Development, 2022, 26, 773-784.	1.3	6
765	Phosphorylation of a Human Microprotein Promotes Dissociation of Biomolecular Condensates. Journal of the American Chemical Society, 2021, 143, 12675-12687.	6.6	20
766	Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story. Current Chemical Biology, 2021, 15, 139-162.	0.2	0
767	Identification of putative actionable alterations in clinically relevant genes in breast cancer. British Journal of Cancer, 2021, 125, 1270-1284.	2.9	1
768	Discovery of N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies. Journal of Medicinal Chemistry, 2021, 64, 12548-12571.	2.9	7

#	Article	IF	Citations
769	Chemical Probes for Understudied Kinases: Challenges and Opportunities. Journal of Medicinal Chemistry, 2022, 65, 1132-1170.	2.9	15
770	Combined Cyclin-Dependent Kinase InhibitionÂOvercomes MAPK/Extracellular Signalâ€“Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I. Journal of Investigative Dermatology, 2022, 142, 613-623.e7.	0.3	4
771	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 1105-1124.	1.1	26
772	Overexpression of cyclinâ€dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance. FEBS Open Bio, 2021, 11, 3126-3141.	1.0	5
773	Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics. Trends in Microbiology, 2021, 29, 836-848.	3.5	29
774	Protein degradation technology: a strategicÂparadigmÂshift in drug discovery. Journal of Hematology and Oncology, 2021, 14, 138.	6.9	45
775	A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling. Cells, 2021, 10, 2391.	1.8	2
776	Identification of CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations. Biomedicines, 2021, 9, 1197.	1.4	10
777	Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2021, 64, 14822-14847.	2.9	19
778	The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer. Scientific Reports, 2021, 11, 18003.	1.6	10
779	CRISPR/Cas9-mediated activation of CDH1 suppresses metastasis of breast cancer in rats. Electronic Journal of Biotechnology, 2021, 53, 54-60.	1.2	6
780	Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy. Acta Pharmaceutica Sinica B, 2021, 11, 2738-2748.	5.7	12
782	Cytotoxic potential of Rheum emodi capped silver nanoparticles and In silico study of human CDK-4/6 proteins with hydroxyanthraquinones. Journal of the Indian Chemical Society, 2021, 98, 100136.	1.3	1
783	Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma. Translational Oncology, 2021, 14, 101148.	1.7	21
784	Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma. Melanoma Research, 2021, Publish Ahead of Print, 495-503.	0.6	2
785	Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study. JTO Clinical and Research Reports, 2021, 2, 100234.	0.6	10
786	Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. European Journal of Medicinal Chemistry, 2021, 221, 113481.	2.6	27
787	Copper exposure induces hepatic G0/G1 cell-cycle arrest through suppressing the Ras/PI3K/Akt signaling pathway in mice. Ecotoxicology and Environmental Safety, 2021, 222, 112518.	2.9	10

#	Article	IF	Citations
788	Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs). Bioorganic Chemistry, 2021, 116, 105347.	2.0	9
789	An insight into the risk factors of brain tumors and their therapeutic interventions. Biomedicine and Pharmacotherapy, 2021, 143, 112119.	2.5	13
790	Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. European Journal of Medicinal Chemistry, 2021, 225, 113768.	2.6	52
791	Synthesis and molecular docking of hybrids ionic azole Schiff bases as novel CDK1 inhibitors and anti-breast cancer agents: In vitro and in vivo study. Journal of Molecular Structure, 2021, 1245, 131041.	1.8	5
792	Design, synthesis, anticancer evaluation and molecular docking study of novel 2,4-dichlorophenoxymethyl-based derivatives linked to nitrogenous heterocyclic ring systems as potential CDK-2 inhibitors. Journal of Molecular Structure, 2022, 1247, 131285.	1.8	16
793	Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma. Cancer Biology and Medicine, 2021, 18, 227-244.	1.4	11
794	OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1. Frontiers in Cell and Developmental Biology, 2020, 8, 617758.	1.8	14
795	CDK4/6 inhibitors: a brief overview and prospective research directions. RSC Advances, 2021, 11, 29227-29246.	1.7	28
796	Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors. Molecular Biology Reports, 2021, 48, 915-925.	1.0	20
797	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer: Basic and Clinical Research, 2021, 15, 117822342199585.	0.6	22
798	TSPAN7 Exerts Anti-Tumor Effects in Bladder Cancer Through the PTEN/PI3K/AKT Pathway. Frontiers in Oncology, 2020, 10, 613869.	1.3	22
799	MicroRNA-301a Promotes Cell Proliferation and Resistance to Apoptosis through PTEN/PI3K/Akt Signaling Pathway in Human Ovarian Cancer. Gynecologic and Obstetric Investigation, 2021, 86, 108-116.	0.7	8
800	Expression and Purification of Recombinant Cyclins and CDKs for Activity Evaluation. Methods in Molecular Biology, 2016, 1336, 9-12.	0.4	1
801	Anticancer Potential of Spider Venom. , 2015, , 1-15.		1
802	Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs, 2021, 81, 317-331.	4.9	173
803	Cyclin D-CDK4/6 functions in cancer. Advances in Cancer Research, 2020, 148, 147-169.	1.9	109
804	Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2. ACS Chemical Biology, 2020, 15, 1759-1764.	1.6	9
805	The role of DOT1L in the proliferation and prognosis of gastric cancer. Bioscience Reports, 2020, 40, .	1.1	21

#	Article	IF	Citations
806	CDK4/6 regulate lysosome biogenesis through TFEB/TFE3. Journal of Cell Biology, 2020, 219, .	2.3	70
811	Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes. Cancer Science, 2020, 111, 2132-2145.	1.7	46
812	Abemaciclib sensitizes HPVâ€negative cervical cancer to chemotherapy via specifically suppressing CDK4/6â€Rbâ€E2F and mTOR pathways. Fundamental and Clinical Pharmacology, 2021, 35, 156-164.	1.0	10
813	Misactivation of Hedgehog signaling causes inherited and sporadic cancers. Journal of Clinical Investigation, 2019, 129, 465-475.	3.9	72
814	CDK4 is an essential insulin effector in adipocytes. Journal of Clinical Investigation, 2015, 126, 335-348.	3.9	65
815	Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2017, 128, 341-358.	3.9	83
816	Dinaciclib induces immunogenic cell death and enhances anti-PD1â€“mediated tumor suppression. Journal of Clinical Investigation, 2018, 128, 644-654.	3.9	144
817	A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib. PLoS ONE, 2017, 12, e0181991.	1.1	2
818	Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocrine-Related Cancer, 2019, 26, R15-R30.	1.6	96
819	Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma. Aging, 2020, 12, 3025-3041.	1.4	19
820	CASC21, a FOXP1 induced long non-coding RNA, promotes colorectal cancer growth by regulating CDK6. Aging, 2020, 12, 12086-12106.	1.4	11
821	Sulforaphane-cysteine downregulates CDK4 /CDK6 and inhibits tubulin polymerization contributing to cell cycle arrest and apoptosis in human glioblastoma cells. Aging, 2020, 12, 16837-16851.	1.4	7
822	Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. Oncotarget, 2016, 7, 56864-56875.	0.8	53
823	Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer. Oncotarget, 2016, 7, 69111-69123.	0.8	26
824	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget, 2016, 7, 68012-68022.	0.8	110
825	The awakening of the CDK10/Cyclin M protein kinase. Oncotarget, 2017, 8, 50174-50186.	0.8	24
826	Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncotarget, 2017, 8, 30252-30264.	0.8	38
827	CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/Î²-catenin pathway. Oncotarget, 2017, 8, 84917-84927.	0.8	19

#	Article	IF	Citations
828	Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Oncotarget, 2017, 8, 67990-68000.	0.8	8
829	Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget, 2017, 8, 59476-59491.	0.8	21
830	Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer. Oncotarget, 2017, 8, 83925-83939.	0.8	34
831	Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E. Oncotarget, 2017, 8, 84743-84760.	0.8	40
832	Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosineâ€™s down regulation of cell cycle processes in OSCC cells. Oncotarget, 2018, 9, 5797-5810.	0.8	14
833	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget, 2018, 9, 6630-6643.	0.8	42
834	Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget, 2018, 9, 5216-5232.	0.8	22
835	Camptothecin induces G2/M phase arrest through the ATM-Chk2-Cdc25C axis as a result of autophagy-induced cytoprotection: Implications of reactive oxygen species. Oncotarget, 2018, 9, 21744-21757.	0.8	33
836	ERÎ±-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget, 2018, 9, 27736-27751.	0.8	11
837	CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. Oncotarget, 2018, 9, 37352-37366.	0.8	33
838	Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget, 2015, 6, 18863-18874.	0.8	18
839	Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. Oncotarget, 2015, 6, 43770-43778.	0.8	79
840	Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition. Oncotarget, 2016, 7, 23757-23771.	0.8	46
841	Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions. Cancer Drug Resistance (Alhambra, Calif), 2020, 3, 48-62.	0.9	20
842	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. Annals of Translational Medicine, 2018, 6, 143-143.	0.7	13
843	CDK14 involvement in proliferation migration and invasion of esophageal cancer. Annals of Translational Medicine, 2019, 7, 681-681.	0.7	20
844	Screening and verifying key genes with poor prognosis in colon cancer through bioinformatics analysis. Translational Cancer Research, 2020, 9, 6720-6732.	0.4	5
845	Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment. Current Medicinal Chemistry, 2019, 26, 1425-1445.	1.2	10

#	Article	IF	Citations
846	Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors. Current Medicinal Chemistry, 2020, 27, 5429-5443.	1.2	5
847	Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy. Current Medicinal Chemistry, 2020, 27, 7264-7288.	1.2	26
848	Germacrone: A Potent Secondary Metabolite with Therapeutic Potential in Metabolic Diseases, Cancer and Viral Infections. Current Drug Metabolism, 2020, 21, 1079-1090.	0.7	21
849	Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Current Drug Targets, 2019, 20, 1180-1202.	1.0	13
850	Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. Current Topics in Medicinal Chemistry, 2020, 20, 1535-1563.	1.0	22
851	Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer. Current Enzyme Inhibition, 2020, 16, 4-19.	0.3	3
852	Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2020, 21, 214-230.	0.9	11
853	CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide. Iranian Journal of Pharmaceutical Research, 2019, 18, 119-131.	0.3	5
854	The Role of Hypoxia-Inducible Factor Post-Translational Modifications in Regulating Its Localisation, Stability, and Activity. International Journal of Molecular Sciences, 2021, 22, 268.	1.8	58
855	CDK5 inhibition inï¿½vitro and in vivo induces cell death inï¿½myeloma and overcomes the obstacle of bortezomib resistance. International Journal of Molecular Medicine, 2020, 45, 1661-1672.	1.8	6
856	CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wildâ€‘type nonâ€‘smallâ€‘cell lung cancer cells. International Journal of Molecular Medicine, 2020, 45, 1783-1792.	1.8	23
857	Mitofusin2 regulates the proliferation and function of fibroblasts: The possible mechanisms underlying pelvic organ prolapse development. Molecular Medicine Reports, 2019, 20, 2859-2866.	1.1	7
858	Capsaicin suppresses breast cancer cell viability by regulating the CDK8/PI3K/Akt/Wnt/Î²â€‘catenin signaling pathway. Molecular Medicine Reports, 2020, 22, 4868-4876.	1.1	25
859	Identification of key candidate genes for colorectal cancer by bioinformatics analysis. Oncology Letters, 2019, 18, 6583-6593.	0.8	14
860	Î±â€‘Solanine inhibits growth and metastatic potential of human colorectal cancer cells. Oncology Reports, 2020, 43, 1387-1396.	1.2	15
861	Apoptosis in Leukemic Cells Induced by Anti-proliferative Coumarin Isolated from the Stem Bark of Fraxinus rhynchophylla. Journal of Microbiology and Biotechnology, 2020, 30, 1214-1221.	0.9	6
862	C-glycosyl flavone from Urginea indica inhibits proliferation & angiogenesis & induces apoptosis via cyclin-dependent kinase 6 in human breast, hepatic & colon cancer cell lines. Indian Journal of Medical Research, 2018, 147, 158.	0.4	12
863	Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World Journal of Gastrointestinal Oncology, 2015, 7, 292.	0.8	15

#	Article	IF	Citations
864	Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. ELife, 2020, 9, .	2.8	27
865	Microarray gene expression profiling in colorectal (HCT116) and hepatocellular (HepG2) carcinoma cell lines treated withMelicope ptelefolialeaf extract reveals transcriptome profiles exhibiting anticancer activity. PeerJ, 2018, 6, e5203.	0.9	16
866	Cancer driver genes: a guilty by resemblance doctrine. PeerJ, 2019, 7, e6979.	0.9	2
867	Design of Nanostructure Materials to Modulate Immunosuppressive Tumour Microenvironments and Enhance Cancer Immunotherapy. Bioanalysis, 2021, , 143-172.	0.1	0
868	Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. Journal of Medicinal Chemistry, 2021, 64, 15189-15213.	2.9	12
869	Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation. Seminars in Cancer Biology, 2021, , .	4.3	7
870	Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective. Drug Discovery Today, 2022, 27, 585-611.	3.2	6
871	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. Journal of Molecular Medicine, 2021, 99, 1691-1710.	1.7	40
872	Targeting transcription cycles in cancer. Nature Reviews Cancer, 2022, 22, 5-24.	12.8	59
873	Regulation of cancer progression by circRNA and functional proteins. Journal of Cellular Physiology, 2022, 237, 373-388.	2.0	22
874	Anti-cancer efficacy includingÂRb-deficient tumorsÂandÂVHL-independent HIF1Î±Âproteasomal destabilizationÂby dual targeting of CDK1 or CDK4/6 and HSP90. Scientific Reports, 2021, 11, 20871.	1.6	9
875	A Combinatorial CRISPRâ€“Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment. Cancer Research, 2021, 81, 6219-6232.	0.4	13
876	Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway in vitro and in vivo. Cell Cycle, 2021, 20, 2494-2506.	1.3	13
877	Genetic variants of cell cycle pathway genes are associated with head and neck squamous cell carcinoma in the Chinese population. Carcinogenesis, 2021, 42, 1337-1346.	1.3	5
878	The Role of Kinase Inhibitors in Cancer Therapies. Biochemistry, 0, , .	0.8	0
879	Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia. Bioorganic Chemistry, 2021, 117, 105431.	2.0	29
880	Cell Cycle-Related Kinases. , 2016, , 1-8.		0
881	Cell cycle targeted anticancer drugs; Present and Future. Natural Science and Discovery, 2016, 2, 1.	0.3	0

#	Article	IF	Citations
882	Cell Cycle Machinery and Its Alterations in Pancreatic Cancer. , 2017, , 1-31.		0
883	The Cell Cycle and Androgen Signaling Interactions in Prostate Cancer. Molecular Pathology Library, 2018, , 381-404.	0.1	1
884	Precision Medicine Based on Next Generation Sequencing and Master Controllers. , 2018, , 1-35.		0
885	Multi-Omics Profiling Establishes the Polypharmacology of FDA Approved CSK4/6 Inhibitors and Its Impact on Drug Response. SSRN Electronic Journal, 0, , .	0.4	1
886	Combination Therapies â€¨in Advanced, Hormone â€¨Receptorâ€“Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2018, 9, .	0.2	3
887	Meme kanseri kanser kÃ¶k hÃ¼crelerinde PD-0332991 uygulanmasÄ±nÄ±n hÃ¼cre dÃ¶ngÃ¼sÃ¼ dÃ¼zenleyici genler Ã¼zerine etkisi. Ege TÄ±p Dergisi, 2018, 57, 36-45.	0.1	0
889	CongrÃ¨s de lâ€™association amÃ©ricaine de recherche contre le cancer â€” AACR 2018. Oncologie, 2018, 20, 49-70.	0.2	0
891	Deletion of FOXL2 by CRISPR promotes cellï¿½cycle G0/G1 restriction in KGN cells. International Journal of Molecular Medicine, 2019, 43, 567-574.	1.8	5
893	A case of recurrent extramammary Pagetâ€™s disease treated with several chemotherapies. Skin Cancer, 2019, 34, 182-185.	0.1	1
897	Nucleolar spindle associated protein 1 (NUSAP1) facilitates proliferation of hepatocellular carcinoma cells. Translational Cancer Research, 2019, 8, 2113-2120.	0.4	4
898	Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2019, 62, 487-498.	0.0	1
902	Regulation and New Treatment Strategies in Breast Cancer. Journal of Life Sciences (Westlake Village,) Tj ETQq1 1 0.784314 rgBT /Ov	1.8	2
903	Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence. Journal of the Advanced Practitioner in Oncology, 2020, 11, 83-96.	0.2	2
904	Progress in Synthesis and Bioactivity Evaluation of Pyrazoloquinazolines. Letters in Drug Design and Discovery, 2020, 17, 104-113.	0.4	3
905	Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts. Medical Science Monitor, 2020, 26, e922561.	0.5	2
909	Expression of biogenesis of ribosomes BRX1 is associated with malignant progression and prognosis in colorectal cancer. Translational Cancer Research, 2020, 9, 5595-5602.	0.4	6
910	Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer. Mini-Reviews in Medicinal Chemistry, 2022, 22, 1197-1215.	1.1	10
911	The Role of CDK4 in the Pathogenesis of Pancreatic Cancer. Healthcare (Switzerland), 2021, 9, 1478.	1.0	1

#	Article	IF	Citations
912	Synthetic approaches for BF2-containing adducts of outstanding biological potential. A review. Arabian Journal of Chemistry, 2022, 15, 103528.	2.3	11
913	Targeting Phosphatases and Kinases: How to Checkmate Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 690306.	1.8	21
914	Reviewing cancerâ€™s biology: an eclectic approach. Journal of the Egyptian National Cancer Institute, 2021, 33, 32.	0.6	14
915	HNRNPU promotes the progression of hepatocellular carcinoma by enhancing CDK2 transcription. Experimental Cell Research, 2021, 409, 112898.	1.2	13
916	Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor. European Journal of Medicinal Chemistry, 2022, 227, 113922.	2.6	24
918	Orientin: A C-Glycosyl Flavonoid that Mitigates Colorectal Cancer. , 2020, , 1-19.		0
919	Antitumour Activity of Muricatacin Isomers and its Derivatives in Human Colorectal Carcinoma Cell HCT116. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 254-263.	0.9	1
920	Telmisartan Exerts Cytotoxicity in Scirrhous Gastric Cancer Cells by Inducing G0/G1 Cell Cycle Arrest. Anticancer Research, 2021, 41, 5461-5468.	0.5	5
921	Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2021, 25, 11097-11112.	1.6	19
922	Synthesis of Novel 2-Thiouracil-5-Sulfonamide Derivatives as Potent Inducers of Cell Cycle Arrest and CDK2A Inhibition Supported by Molecular Docking. International Journal of Molecular Sciences, 2021, 22, 11957.	1.8	6
923	Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer. Meditsinskiy Sovet, 2020, , 27-42.	0.1	0
924	Kanserin erken teÅŸhisi, prognozu ve tedavisinde mikroRNA-124â€™Ã¼n yeri. Zeynep Kamil Tip Bulteni, 2020, 51, 179-185.	0.1	0
925	Role of the androgen receptor in triple-negative breast cancer. Clinical Advances in Hematology and Oncology, 2016, 14, 186-93.	0.3	68
926	Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discovery Medicine, 2016, 21, 65-74.	0.5	59
928	Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2018, 9, 43-54.	0.2	5
929	LncRNA PCAT-1 plays an oncogenic role in epithelial ovarian cancer by modulating cyclinD1/CDK4 expression. International Journal of Clinical and Experimental Pathology, 2019, 12, 2148-2156.	0.5	7
930	Regulation and New Treatment Strategies in Breast Cancer. Journal of Life Sciences (Westlake Village,) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.8	2
931	Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells. Reports of Biochemistry and Molecular Biology, 2020, 8, 438-445.	0.5	4

#	Article	IF	Citations
932	Epigenetic mechanisms and the hallmarks of cancer: an intimate affair. American Journal of Cancer Research, 2020, 10, 1954-1978.	1.4	21
933	Cyclin E: a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle. American Journal of Translational Research (discontinued), 2020, 12, 5170-5187.	0.0	5
934	Inhibition of Cyclin-dependent Kinase (CDK) Decreased Survival of NB4 Leukemic Cells: Proposing a p53-Independent Sensitivity of Leukemic Cells to Multi-CDKs Inhibitor AT7519. Iranian Journal of Pharmaceutical Research, 2020, 19, 144-155.	0.3	2
935	The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer. American Journal of Cancer Research, 2020, 10, 4325-4341.	1.4	2
936	CDK inhibitors in cancer therapy, an overview of recent development. American Journal of Cancer Research, 2021, 11, 1913-1935.	1.4	20
937	Overexpression of miR-138-5p Sensitizes Taxol-Resistant Epithelial Ovarian Cancer Cells through Targeting Cyclin-Dependent Kinase 6. Gynecologic and Obstetric Investigation, 2021, 86, 533-541.	0.7	4
938	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. MedComm, 2021, 2, 514-530.	3.1	12
939	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. Blood, 2022, 139, 1541-1556.	0.6	23
940	Adamantane-Substituted Purines and Their Î²-Cyclodextrin Complexes: Synthesis and Biological Activity. International Journal of Molecular Sciences, 2021, 22, 12675.	1.8	8
942	DNA damage response proteins synergistically affect the cancer prognosis and resistance. Free Radical Biology and Medicine, 2022, 178, 174-188.	1.3	6
943	High Expression of C1ORF112 Predicts a Poor Outcome: A Potential Target for the Treatment of Low-Grade Gliomas. Frontiers in Genetics, 2021, 12, 710944.	1.1	6
944	Recent Trends in Rationally Designed Molecules as Kinase Inhibitors. Current Medicinal Chemistry, 2023, 30, 1529-1567.	1.2	4
945	Investigation of the electronic properties of solvents (water, benzene, methanol) using IEFPCM model, spectroscopic investigation with docking and MD simulations of a thiadiazole derivative with anti-tumor activities. Journal of Molecular Liquids, 2022, 348, 118061.	2.3	3
946	Novel 1,3,5â€triazineâ€nicotinohydrazide derivatives induce cell arrest and apoptosis in osteosarcoma cancer cells and inhibit osteosarcoma in a patientâ€derived orthotopic xenograft mouse model. Chemical Biology and Drug Design, 2022, 99, 320-330.	1.5	2
947	5-epi-Sinuleptolide from Soft Corals of the Genus Sinularia Exerts Cytotoxic Effects on Pancreatic Cancer Cell Lines via the Inhibition of JAK2/STAT3, AKT, and ERK Activity. Molecules, 2021, 26, 6932.	1.7	7
948	The circular RNA circSLC7A11 functions as a mir-330-3p sponge to accelerate hepatocellular carcinoma progression by regulating cyclin-dependent kinase 1 expression. Cancer Cell International, 2021, 21, 636.	1.8	5
949	KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. Critical Reviews in Oncology/Hematology, 2021, 168, 103524.	2.0	7
950	Telmisartan-Induced Cytotoxicity <i>via</i> G₂/M Phase Arrest in Renal Cell Carcinoma Cell Lines. Biological and Pharmaceutical Bulletin, 2021, 44, 1878-1885.	0.6	2

#	Article	IF	Citations
951	Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors. Oncogenesis, 2021, 10, 83.	2.1	10
952	Cell Cycle Regulation. , 2021, , 420-429.		0
953	Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. European Journal of Medicinal Chemistry, 2022, 228, 114024.	2.6	4
954	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancerâ€"findings from the RIBECCA trial. European Journal of Cancer, 2022, 162, 45-55.	1.3	12
955	Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy. European Journal of Medicinal Chemistry, 2022, 229, 114056.	2.6	15
956	SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-PHENYLPYRIDO[2,3-D] PYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS. Indian Drugs, 2019, 56, 50-58.	0.1	0
958	Dynamical Methods to Study Interaction in Proteins Facilitating Molecular Understanding of Cancer. , 2022, , 2231-2247.		0
959	Recent Developments of Flavonoids with Various Activities. Current Topics in Medicinal Chemistry, 2022, 22, 305-329.	1.0	13
960	CDK4/6 inhibitors induce replication stress to cause longâ€term cell cycle withdrawal. EMBO Journal, 2022, 41, e108599.	3.5	48
961	Small-molecule degraders of cyclin-dependent kinase protein: a review. Future Medicinal Chemistry, 2022, 14, 167-185.	1.1	5
962	SÄ°KLÄ°N BAÄžIMLI KÄ°NAZ 4/6 VE Ä°NHÄ°BÄ°TÃ–RLERÄ°. Ankara Universitesi Eczacilik Fakultesi Dergisi, 0, , 193-208.	0.8	0
963	Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. JCO Precision Oncology, 2022, 6, e2100002.	1.5	36
964	Cancer and cell cycle. , 2022, , 91-102.		0
966	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. Cancers, 2022, 14, 679.	1.7	4
967	Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges. JCO Precision Oncology, 2022, 6, e2100211.	1.5	19
968	New cell cycle checkpoint pathways regulators with 2-Oxo-indoline scaffold as potential anticancer agents: Design, synthesis, biological activities and in silico studies. Bioorganic Chemistry, 2022, 120, 105622.	2.0	5
969	CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188680.	3.3	4
970	Discovery and Optimization of Highly Selective Inhibitors of CDK5. Journal of Medicinal Chemistry, 2022, 65, 3575-3596.	2.9	9

#	Article	IF	Citations
971	CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future Oncology, 2022, 18, 1143-1157.	1.1	8
972	Alpinetin: A Review of Its Pharmacology and Pharmacokinetics. Frontiers in Pharmacology, 2022, 13, 814370.	1.6	18
973	Emodin-8-O-Î²-D-glucopyranoside, a natural hydroxyanthraquinone glycoside from plant, suppresses cancer cell proliferation via p21-CDKs-Rb axis. Toxicology and Applied Pharmacology, 2022, 438, 115909.	1.3	1
974	Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2022, 65, 857-875.	2.9	8
975	Oxidative Stressâ€“a Double Edged Sword in Cancer. , 2021, , 1-18.		0
976	Oxidative Stress in Cancer: Therapeutic Implications of Small-Molecule Kinase Inhibitors. , 2022, , 1-17.		0
977	An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers, 2022, 14, 1113.	1.7	6
978	Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence. Cell Death and Disease, 2022, 13, 163.	2.7	8
979	Biosynthesis of Zinc Oxide nanoparticles using Origanum majorana L. leaf extract, its antioxidant and cytotoxic activities. Materials Technology, 2022, 37, 2522-2531.	1.5	12
980	Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies. Cancers, 2022, 14, 1265.	1.7	7
981	CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer. Cancers, 2022, 14, 989.	1.7	8
982	Tumor Dormancy: Biologic and Therapeutic Implications. World Journal of Oncology, 2022, 13, 8-19.	0.6	9
983	Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment. International Journal of Molecular Sciences, 2022, 23, 2477.	1.8	7
984	Targeting CDK4/6 for Anticancer Therapy. Biomedicines, 2022, 10, 685.	1.4	11
985	Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. Journal of Medicinal Chemistry, 2022, 65, 6356-6389.	2.9	25
986	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery, 2022, 21, 440-462.	21.5	58
987	The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Frontiers in Pharmacology, 2022, 13, 861642.	1.6	7
988	Damnacanthal isolated from morinda species inhibited ovarian cancer cell proliferation and migration through activating autophagy. Phytomedicine, 2022, 100, 154084.	2.3	12

#	Article	IF	Citations
989	Cellular Senescence and Ageing: Mechanisms and Interventions. Frontiers in Aging, 2022, 3, .	1.2	34
990	CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Reports, 2022, 38, 110448.	2.9	48
991	New Advances in Targeted Therapy of HER2-Negative Breast Cancer. Frontiers in Oncology, 2022, 12, 828438.	1.3	7
992	NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1. Cancer Science, 2023, 114, 896-907.	1.7	8
993	Shining Light on Protein Kinase Biomarkers with Fluorescent Peptide Biosensors. Life, 2022, 12, 516.	1.1	1
994	Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma. Cell Cycle, 2022, 21, 1103-1119.	1.3	2
995	Targeting CDK4 and CDK6 in cancer. Nature Reviews Cancer, 2022, 22, 356-372.	12.8	125
996	Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib. Scientific Reports, 2022, 12, 5706.	1.6	10
997	Huangqin Tang Interference With Colitis Associated Colorectal Cancer Through Regulation of Epithelial Mesenchymal Transition and Cell Cycle. Frontiers in Pharmacology, 2022, 13, 837217.	1.6	4
998	Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines. Saudi Pharmaceutical Journal, 2022, 30, 726-734.	1.2	11
999	Phosphorylated MED1 links transcription recycling and cancer growth. Nucleic Acids Research, 2022, 50, 4450-4463.	6.5	2
1000	Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers. Cureus, 2022, 14, e23901.	0.2	1
1001	Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma. Biomedicine and Pharmacotherapy, 2022, 149, 112888.	2.5	0
1002	Novel pyridine and pyrimidine derivatives as promising anticancer agents: A review. Arabian Journal of Chemistry, 2022, 15, 103846.	2.3	53
1003	Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27. Cell Cycle, 2022, 21, 12-32.	1.3	7
1004	Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast, 2022, 62, S70-S79.	0.9	10
1005	Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer. Cancers, 2021, 13, 6282.	1.7	7
1007	Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. Acta Pharmaceutica Sinica B, 2022, 12, 1781-1804.	5.7	27

#	Article	IF	Citations
1008	Differential Expression of Mitosis and Cell Cycle Regulatory Genes during Recovery from an Acute Respiratory Virus Infection. Pathogens, 2021, 10, 1625.	1.2	3
1009	Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. Endocrinology, 2022, 163, .	1.4	8
1010	Role of Genetic Variations inCDK2,CCNE1andp27^{KIP1}in Prostate Cancer. Cancer Genomics and Proteomics, 2022, 19, 362-371.	1.0	2
1011	CDK9 inhibitors in cancer research. RSC Medicinal Chemistry, 2022, 13, 688-710.	1.7	10
1012	Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2â^' Breast Cancer at a Single Cancer Center. Oncologist, 2022, 27, 646-654.	1.9	7
1013	â€˜Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomicsâ€™. Frontiers in Molecular Biosciences, 2022, 9, 783494.	1.6	6
1022	Hotair promotes the migration and proliferation in ovarian cancer by miR-222-3p/CDK19 axis. Cellular and Molecular Life Sciences, 2022, 79, 254.	2.4	5
1023	Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2022, 65, 6729-6747.	2.9	7
1024	Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1227-1240.	2.5	15
1027	From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. Journal of Medicinal Chemistry, 2022, 65, 6390-6418.	2.9	22
1028	Overcoming Cancer Drug Resistance Utilizing PROTAC Technology. Frontiers in Cell and Developmental Biology, 2022, 10, 872729.	1.8	32
1029	The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer. Cancers, 2022, 14, 2101.	1.7	11
1030	Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-8.	0.7	3
1031	Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications. , 2022, 39, 106.		53
1032	A Toolbox of Fluorescent Peptide Biosensors to Highlight Protein Kinases in Complex Samples: Focus on Cyclinâ€Dependent Kinases. European Journal of Organic Chemistry, 2022, 2022, .	1.2	2
1033	CDC7-independent G1/S transition revealed by targeted protein degradation. Nature, 2022, 605, 357-365.	13.7	38
1034	Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior. Frontiers in Pharmacology, 2022, 13, .	1.6	6
1035	Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene, 2022, 41, 3303-3315.	2.6	16

#	Article	IF	Citations
1036	Abemaciclib and Vacuolin-1 induce vacuole-like autolysosome formation â€“ A new tool to study autophagosome-lysosome fusion. Biochemical and Biophysical Research Communications, 2022, 614, 191-197.	1.0	1
1037	A patent review of anticancer CDK2 inhibitors (2017â€“present). Expert Opinion on Therapeutic Patents, 2022, 32, 885-898.	2.4	5
1038	Vortex keratopathy associated with ribociclib. Journal of Oncology Pharmacy Practice, 2023, 29, 230-232.	0.5	3
1039	Nanotechnology-based targeted delivery systems for protein kinase inhibitors in Cancer therapy. , 2022, , 747-779.		0
1040	Pharmacological properties of indirubin and its derivatives. Biomedicine and Pharmacotherapy, 2022, 151, 113112.	2.5	20
1041	Discovery of novel benzofuro[3,2-b]quinoline derivatives as dual CDK2/Topo I inhibitors. Bioorganic Chemistry, 2022, 126, 105870.	2.0	3
1042	Novel Azine Linked Hybrids of 2-Indolinone and Thiazolodinone Scaffolds as CDK2 Inhibitors with Potential Anticancer Activity: In Silico Design, Synthesis, Biological, Molecular Dynamics and Binding Free Energy Studies. Bioorganic Chemistry, 2022, 126, 105884.	2.0	6
1043	Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy. Trends in Cancer, 2022, 8, 711-725.	3.8	12
1044	Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. BMJ Open, 2022, 12, e056374.	0.8	3
1045	The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?. Cancers, 2022, 14, 2709.	1.7	2
1046	CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. Frontiers in Oncology, 0, 12, .	1.3	14
1047	Synthesis of novel 1,2,3-triazole hybrids of methyl Î²-orsellinate with capabilities to arrest cell cycle and induce apoptosis in breast cancer cells (MCF-7). Monatshefte FÃ¼r Chemie, 0, , .	0.9	1
1048	Stable H-bond networks are crucial for selective CDK4 inhibition revealed from comprehensive in silico investigation. Computational Biology and Chemistry, 2022, 99, 107699.	1.1	0
1049	Defining the molecular underpinnings controlling cardiomyocyte proliferation. Clinical Science, 2022, 136, 911-934.	1.8	2
1050	Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer. Mini-Reviews in Medicinal Chemistry, 2023, 23, 412-428.	1.1	3
1051	Pyrazolopyrimidines as attractive pharmacophores in efficient drug design: A recent update. Archiv Der Pharmazie, 0, , .	2.1	3
1052	Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer. Molecular Cancer Therapeutics, 2022, 21, 1473-1484.	1.9	1
1053	Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CD3+CD56+ NKT-Like Cells. Journal of Oncology, 2022, 2022, 1-14.	0.6	1

#	Article	IF	Citations
1054	Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. International Journal of Molecular Sciences, 2022, 23, 6547.	1.8	11
1055	A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships. European Journal of Medicinal Chemistry, 2022, 239, 114527.	2.6	11
1056	Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis. Cancer Letters, 2022, 543, 215781.	3.2	27
1057	EFFICACY OF PALBOCICLIB ON POSITIVE METASTATIC BREAST CANCER RECEPTOR, IN REAL WORLD DATA STUDIES AND OUR EXPERIENCE IN ONCOLOGY SERVICE. , 2022, , 127-130.		0
1058	Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1585-1606.	1.2	9
1059	Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies. Reproduction and Fertility, 2022, 3, R147-R162.	0.6	14
1060	Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1884-1902.	2.5	35
1061	Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics. ACS Omega, 2022, 7, 25844-25852.	1.6	10
1062	CDK1 Promotes Epithelialâ€“Mesenchymal Transition and Migration of Head and Neck Squamous Carcinoma Cells by Repressing âˆ†Np63Î±-Mediated Transcriptional Regulation. International Journal of Molecular Sciences, 2022, 23, 7385.	1.8	5
1063	Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth. IScience, 2022, 25, 104752.	1.9	2
1064	Tâ€17, a novel cyclinâ€dependent kinases/histone deacetylases dual inhibitor, induces cancer cells death through cell cycle arrest and apoptosis. Drug Development Research, 0, , .	1.4	1
1065	Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. Expert Opinion on Investigational Drugs, 2022, 31, 933-944.	1.9	0
1066	Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas. Cancers, 2022, 14, 3611.	1.7	3
1067	Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications. International Journal of Biological Macromolecules, 2022, 218, 394-408.	3.6	13
1068	Anti-tumor pharmacology of natural products targeting mitosis. Cancer Biology and Medicine, 2022, 19, 1-28.	1.4	5
1069	Hoxa5 Inhibits the Proliferation and Induces Adipogenic Differentiation of Subcutaneous Preadipocytes in Goats. Animals, 2022, 12, 1859.	1.0	4
1070	Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study. , 2022, 39, .		27
1071	CDK 4/6 inhibitors for the treatment of meningioma. Frontiers in Oncology, 0, 12, .	1.3	9

#	Article	IF	Citations
1072	CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	3
1073	Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13. Journal of Medicinal Chemistry, 2022, 65, 11066-11083.	2.9	18
1074	Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	2
1075	Computational Investigations of Coumarin Derivatives as Cyclindependent Kinase 9 Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. Current Computer-Aided Drug Design, 2022, 18, 363-380.	0.8	1
1076	The HPV16E7 Affibody as a Novel Potential Therapeutic Agent for Treating Cervical Cancer Is Likely Internalized through Dynamin and Caveolin-1 Dependent Endocytosis. Biomolecules, 2022, 12, 1114.	1.8	0
1077	Effect of Titanium Dioxide Nanoparticles on Mammalian Cell Cycle In Vitro: A Systematic Review and Meta-Analysis. Chemical Research in Toxicology, 2022, 35, 1435-1456.	1.7	7
1078	Liproxstatinâ€'1 induces cell cycle arrest, apoptosis, and caspaseâ€'3/GSDMEâ€'dependent secondary pyroptosis in K562 cells. International Journal of Oncology, 2022, 61, .	1.4	6
1079	Benzimidazoleâ€based protein kinase inhibitors: Current perspectives in targeted cancer therapy. Chemical Biology and Drug Design, 2022, 100, 656-673.	1.5	15
1080	Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-23.	1.9	3
1081	Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis. Supportive Care in Cancer, 2022, 30, 9071-9078.	1.0	5
1082	CDK4: a master regulator of the cell cycle and its role in cancer. Genes and Cancer, 2022, 13, 21-45.	0.6	18
1083	Design, synthesis, and anticancer activity of three novel palbociclib derivatives. Frontiers in Oncology, 0, 12, .	1.3	2
1084	CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. Frontiers in Oncology, 0, 12, .	1.3	3
1085	P62/SQSTM1 mediates the autophagy-lysosome degradation of CDK2 protein undergoing PI3KÎ±/AKT T308 inhibition. Biochemical and Biophysical Research Communications, 2022, 627, 5-11.	1.0	2
1086	Roles of phosphatases in eukaryotic DNA replication initiation control. DNA Repair, 2022, 118, 103384.	1.3	1
1087	Synthesis of pyridine derivatives for diverse biological activity profiles: A review. , 2023, , 605-625.		9
1088	Cell Division/Death: Cell Cycle â€" Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors. , 2022, , .		0
1089	Discovery of Novel and Potent Tacrine Derivatives as CDK2 Inhibitors. New Journal of Chemistry, 0, , .	1.4	0

#	Article	IF	Citations
1090	A revised synthesis of 6-alkoxy-2-aminopurines with late-stage convergence allowing for increased molecular complexity. New Journal of Chemistry, 2022, 46, 17040-17048.	1.4	2
1091	Oxidative Stress: A Double Edged Sword in Cancer. , 2022, , 135-151.		0
1092	Oxidative Stress in Cancer: Therapeutic Implications of Small-Molecule Kinase Inhibitors. , 2022, , 3809-3825.		0
1093	Long noncoding RNA HOXC-AS3 interacts with CDK2 to promote proliferation in hepatocellular carcinoma. Biomarker Research, 2022, 10, .	2.8	2
1094	<scp>PFKFB4</scp> facilitates palbociclib resistance in oestrogen receptorâ€positive breast cancer by enhancing stemness. Cell Proliferation, 2023, 56, .	2.4	5
1095	A Perspective Study on the RTK, PI3K, Bâ€Raf, CDK and the Multiâ€Protein Targeting in Medicinal Chemistry. Chemistry and Biodiversity, 2022, 19, .	1.0	2
1096	Ubiquitin-related lncRNAs: The new tool for prognosis prediction in prostate cancer. Frontiers in Oncology, 0, 12, .	1.3	0
1097	Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	4
1098	Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. Npj Precision Oncology, 2022, 6, .	2.3	10
1099	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	33
1100	Discovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors. ACS Medicinal Chemistry Letters, 0, , .	1.3	3
1101	Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kineticâ€“pharmacodynamic model of neutropenia. Cancer Chemotherapy and Pharmacology, 0, , .	1.1	1
1102	Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. Gynecologic Oncology, 2022, 167, 540-546.	0.6	4
1103	A review on the role of cyclin dependent kinases in cancers. Cancer Cell International, 2022, 22, .	1.8	24
1104	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. Cancers, 2022, 14, 5206.	1.7	14
1105	PDZK1-interacting protein 1(PDZK1IP1) promotes subcutaneous preadipocyte proliferation in goats. Animal Biotechnology, 0, , 1-11.	0.7	2
1106	The targets of aspirin in bladder cancer: bioinformatics analysis. BMC Urology, 2022, 22, .	0.6	0
1107	Crystal structure of the CDK11 kinase domain bound to the small-molecule inhibitor OTS964. Structure, 2022, , .	1.6	3

#	Article	IF	Citations
1108	The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus. Kidney International, 2023, 103, 343-356.	2.6	1
1109	DJ-1 promotes osteosarcoma progression through activating CDK4/RB/E2F1 signaling pathway. Frontiers in Oncology, 0, 12, .	1.3	1
1110	A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Oncology, 2022, 135, 106219.	0.8	5
1111	IKBIP, a novel glioblastoma biomarker, maintains abnormal proliferation of tumor cells by inhibiting the ubiquitination and degradation of CDK4. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166571.	1.8	3
1112	Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptorâ€'positive/human epidermal growth factor receptor 2â€'negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. Breast, 2022, 66, 324-331.	0.9	1
1113	Inhibitory Effects of Rabdosia rubescens in Esophageal Squamous Cell Carcinoma: Network Pharmacology and Experimental Validation. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-16.	0.5	0
1114	Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer. Journal of Medicinal Chemistry, 2022, 65, 15102-15122.	2.9	5
1115	tRF-3013b inhibits gallbladder cancer proliferation by targeting TPRG1L. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	5
1116	Discovery of Novel and Potent Inhibitors of Cyclinâ€Dependent Kinases 7 and 9: Design, Synthesis, Structureâ€Activity Relationship Analysis and Biological Evaluation. ChemMedChem, 0, , .	1.6	3
1117	Emerging approaches to CDK inhibitor development, a structural perspective. RSC Chemical Biology, 2023, 4, 146-164.	2.0	4
1118	Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188842.	3.3	4
1119	Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer. Frontiers in Oncology, 0, 12, .	1.3	2
1120	Enriching Chemical Space of Bioactive Scaffolds by New Ring Systems: Benzazocines and Their Metal Complexes as Potential Anticancer Drugs. Inorganic Chemistry, 2022, 61, 20445-20460.	1.9	6
1121	Screening of Hub Genes in Hepatocellular Carcinoma Based on Network Analysis and Machine Learning. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-32.	0.7	0
1122	The Role of miRNAs, circRNAs and Their Interactions in Development and Progression of Hepatocellular Carcinoma: An Insilico Approach. Genes, 2023, 14, 13.	1.0	3
1123	CDK inhibitors from past to present: A new wave of cancer therapy. Seminars in Cancer Biology, 2023, 88, 106-122.	4.3	15
1124	Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion. Oncology Reports, 2022, 49, .	1.2	4
1125	Integrative analysis of transcriptome and metabolome reveals probiotic effects on cecal metabolism in broilers. Journal of the Science of Food and Agriculture, 0, , .	1.7	0

#	Article	IF	Citations
1126	An Activity-Based Oxaziridine Platform for Identifying and Developing Covalent Ligands for Functional Allosteric Methionine Sites: Redox-Dependent Inhibition of Cyclin-Dependent Kinase 4. Journal of the American Chemical Society, 2022, 144, 22890-22901.	6.6	13
1127	Gene amplification-driven lncRNA SNHG6 promotes tumorigenesis via epigenetically suppressing p27 expression and regulating cell cycle in nonâ€“small cell lung cancer. Cell Death Discovery, 2022, 8, .	2.0	6
1128	Preclinical evaluation of <scp>CDK4</scp> phosphorylation predicts high sensitivity of pleural mesotheliomas to <scp>CDK4</scp>/6 inhibition. Molecular Oncology, 0, , .	2.1	5
1129	Synthesis, Cytotoxic Evaluation, and Structure-Activity Relationship of Substituted Quinazolinones as Cyclin-Dependent Kinase 9 Inhibitors. Molecules, 2023, 28, 120.	1.7	2
1130	Single-cell transcriptome analysis reveals a cancer-associated fibroblast marker gene signature in hepatocellular carcinoma that predicts prognosis. , 2023, 2, 16-25.		1
1131	Design, synthesis and biological evaluation of novel 9-methyl-9H-purine and thieno[3, 2-d]pyrimidine derivatives as potent mTOR inhibitors. Bioorganic Chemistry, 2023, 132, 106356.	2.0	1
1132	A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
1133	Progress of small molecules for targeted protein degradation: PROTACs and other technologies. Drug Development Research, 2023, 84, 337-394.	1.4	6
1134	Triazole-fused pyrimidines in target-based anticancer drug discovery. European Journal of Medicinal Chemistry, 2023, 249, 115101.	2.6	13
1135	Nano-Zirconium Dioxide Catalyzed Multicomponent Synthesis of Bioactive Pyranopyrazoles That Target Cyclin Dependent Kinase 1 in Human Breast Cancer Cells. Biomedicines, 2023, 11, 172.	1.4	4
1136	Study on the mechanism of action of Scutellaria barbata on hepatocellular carcinoma based on network pharmacology and bioinformatics. Frontiers in Pharmacology, 0, 13, .	1.6	1
1137	LDHA as a regulator of T cell fate and its mechanisms in disease. Biomedicine and Pharmacotherapy, 2023, 158, 114164.	2.5	8
1138	Cooperation of structural motifs controls drug selectivity in cyclin-dependent kinases: an advanced theoretical analysis. Briefings in Bioinformatics, 2023, 24, .	3.2	4
1139	Targeted Protein Degradation Induced by HEMTACs Based on HSP90. Journal of Medicinal Chemistry, 2023, 66, 733-751.	2.9	7
1140	Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions. Frontiers in Oncology, 0, 13, .	1.3	1
1141	Catechol-O-methyl transferase suppresses cell invasion and interplays with MET signaling in estrogen dependent breast cancer. Scientific Reports, 2023, 13, .	1.6	3
1142	The genomic regulation of metastatic dormancy. Cancer and Metastasis Reviews, 2023, 42, 255-276.	2.7	2
1143	Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction. Oncogene, 2023, 42, 869-880.	2.6	1

#	Article	IF	Citations
1144	Anti-cancer drug molecules targeting cancer cell cycle and proliferation. Advances in Protein Chemistry and Structural Biology, 2023, , 343-395.	1.0	4
1145	Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment. International Journal of Molecular Sciences, 2023, 24, 2236.	1.8	5
1147	Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. Molecules, 2023, 28, 943.	1.7	3
1148	Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer. Advances in Protein Chemistry and Structural Biology, 2023, , 1-19.	1.0	3
1149	CDK regulatorsâ€"Cell cycle progression or apoptosisâ€"Scenarios in normal cells and cancerous cells. Advances in Protein Chemistry and Structural Biology, 2023, , 125-177.	1.0	9
1150	Cell Cycle-Related Gene SPC24: A Novel Potential Diagnostic and Prognostic Biomarker for Laryngeal Squamous Cell Cancer. BioMed Research International, 2023, 2023, 1-14.	0.9	1
1151	Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Communications, 2023, 14, .	5.8	7
1153	Cyclin-dependent kinase inhibitors in malignant hematopoiesis. Frontiers in Oncology, 0, 12, .	1.3	4
1154	Therapeutic targets in cancer treatment: Cell cycle proteins. Advances in Protein Chemistry and Structural Biology, 2023, , 313-342.	1.0	3
1155	Drug discovery: Standing on the shoulders of giants. , 2023, , 207-338.		0
1156	A comprehensive analysis of the role of molecular docking in the development of anticancer agents against the cell cycle CDK enzyme. Biocell, 2023, 47, 707-729.	0.4	3
1157	CDk Inhibitor for Treatment of Breast Cancer. , 2023, , 313-333.		0
1158	Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation. European Journal of Medicinal Chemistry, 2023, 254, 115342.	2.6	4
1159	Integrative proteogenomic characterization of early esophageal cancer. Nature Communications, 2023, 14, .	5.8	8
1160	Computational analysis of protein-ligand interaction by targeting a cell cycle restrainer. Computer Methods and Programs in Biomedicine, 2023, 231, 107367.	2.6	18
1161	The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer. International Journal of Molecular Sciences, 2023, 24, 2848.	1.8	4
1162	Identification of potential ATP-competitive cyclin-dependent kinase 1 inhibitors: De novo drug generation, molecular docking, and molecular dynamics simulation. Computers in Biology and Medicine, 2023, 155, 106645.	3.9	6
1163	Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer. Journal of Oncology Pharmacy Practice, 0, , 107815522311565.	0.5	2

#	Article	IF	Citations
1164	Search for immunomodulatory compounds with antiproliferative activity against melanoma. Biomedicine and Pharmacotherapy, 2023, 160, 114374.	2.5	0
1165	Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases. Viruses, 2023, 15, 568.	1.5	2
1166	Knockdown of UBE2I inhibits tumorigenesis and enhances chemosensitivity of cholangiocarcinoma via modulating p27kip1 nuclear export. Molecular Carcinogenesis, 2023, 62, 700-715.	1.3	2
1167	Deregulation of the cyclin-dependent kinase inhibitor p27 as a putative candidate for transformation in <i>Chlamydia trachomatis</i> infected mesenchymal stem cells. AIMS Microbiology, 2023, 9, 131-150.	1.0	0
1168	Therapeutic Implications of CDKs in Breast Cancer. , 2023, , 233-252.		0
1169	Introduction to Cell Cycle and Its Regulators. , 2023, , 53-82.		0
1170	CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis. , 2023, , 175-194.		0
1171	Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers. , 2023, , 211-232.		0
1172	Cell Cycle Dysregulation in Breast Cancer. , 2023, , 103-131.		2
1173	CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. , 2023, , 291-311.		0
1174	CDK1 Dysregulation in Breast Cancer. , 2023, , 195-210.		1
1175	Role of identified proteins in the proteome profiles of CDK4/6 inhibitor-resistant breast cancer cell lines. Molecular Omics, 0, , .	1.4	1
1176	Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022. International Journal of Molecular Sciences, 2023, 24, 5190.	1.8	2
1177	Evodiamine inhibits malignant progression of ovarian cancer cells by regulating lncRNAâ€NEAT1/miRâ€152â€3p/CDK19 axis. Chemical Biology and Drug Design, 0, , .	1.5	2
1178	Position paper on CDK4/6 inhibitors in early breast cancer. Memo - Magazine of European Medical Oncology, 0, , .	0.3	0
1179	Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2â^' Metastatic Breast Cancer in Postmenopausal Women in the USA. Pharmacoeconomics, 2023, 41, 709-718.	1.7	6
1180	Synthesis and inÂvitro anticancer activity of some 2-oxindoline derivatives as potential CDK2 inhibitors. Journal of Biomolecular Structure and Dynamics, 2023, 41, 15009-15022.	2.0	1
1181	Antiproliferative Activity, Multikinase Inhibition, Apoptosis- Inducing Effects and Molecular Docking of Novel Isatinâ€"Purine Hybrids. Medicina (Lithuania), 2023, 59, 610.	0.8	6

#	Article	IF	Citations
1182	Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface. Cancers, 2023, 15, 1822.	1.7	0
1183	Small molecule â€˜4abâ€™ induced autophagy and endoplasmic reticulum stress-mediated death of aggressive cancer cells grown under adherent and floating conditions. , 2023, 40, .		3
1184	An Overview of CDK Enzyme Inhibitors in Cancer Therapy. Current Cancer Drug Targets, 2023, 23, 603-619.	0.8	2
1185	Palbociclib and Michael-acceptor hybrid compounds as CDK4/6 covalent inhibitors: Improved potency, broad anticancer spectrum and overcoming drug resistance. Bioorganic and Medicinal Chemistry, 2023, 84, 117263.	1.4	2
1186	ncRNAs-mediated overexpression of STIL predict unfavorable prognosis and correlated with the efficacy of immunotherapy of hepatocellular carcinoma. Cancer Cell International, 2023, 23, .	1.8	0
1187	A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022). Expert Opinion on Therapeutic Patents, 2023, 33, 67-87.	2.4	5
1188	eIF3d: A driver of noncanonical capâ€“dependent translation of specific mRNAs and a trigger of biological/pathological processes. Journal of Biological Chemistry, 2023, 299, 104658.	1.6	4
1189	A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans. Frontiers in Pharmacology, 0, 14, .	1.6	1
1190	Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
1191	Computational screening and structural analysis of Gly201Arg and Gly201Asp missense mutations in human cyclin-dependent kinase 4 protein. Advances in Protein Chemistry and Structural Biology, 2023, , 57-96.	1.0	0
1192	Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of tripleâ€negative breast cancer (TNBC). Drug Development Research, 2023, 84, 629-653.	1.4	3
1194	Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. Cancers, 2023, 15, 2204.	1.7	10
1197	<scp>CDK6</scp> is activated by the atypical cyclin I to promote <scp>E2F</scp>â€mediated gene expression and cancer cell proliferation. Molecular Oncology, 2023, 17, 1228-1245.	2.1	0
1198	Structure-based virtual screening for the identification of novel Greatwall kinase inhibitors. , 2023, , 101-116.		0
1200	Discovery of Benzodiazepine-Based Inhibitors of the E2 Enzyme UBCH10 from a Cell-Based p21 Degradation Screen. ACS Chemical Biology, 2023, 18, 1039-1046.	1.6	2
1232	Proteinâ€“Protein Interactions in Cancer. , 2023, , 43-100.		0
1245	Targeting immune checkpoints for cancer therapy. , 2023, , 95-134.		0
1247	Flow cytometry-assisted quantification of cell cycle arrest in cancer cells treated with CDK4/6 inhibitors. Methods in Cell Biology, 2024, , 197-212.	0.5	0

#	Article	IF	Citations
1249	Kisquali (Ribociclib): A promising therapeutic candidate against breast cancer. AIP Conference Proceedings, 2023, , .	0.3	0
1250	Cyclin-dependent kinase 2 (CDK2). , 2024, , 51-62.		1
1267	Discovery of small molecule degraders for modulating cell cycle. Frontiers of Medicine, 2023, 17, 823-854.	1.5	0
1272	Regulation and targeting of SREBP-1 in hepatocellular carcinoma. Cancer and Metastasis Reviews, 0, , .	2.7	3
1273	RECENT ADVANCES IN THE DISCOVERY OF CYCLIN-DEPENDENT KINASE 2 (CDK2) SELECTIVE INHIBITORS. Medicinal Chemistry Reviews, 0, , 283-311.	0.1	0
1284	The CDK4/6 inhibitor revolution â€" a game-changing era for breast cancer treatment. Nature Reviews Clinical Oncology, 2024, 21, 89-105.	12.5	4
1305	Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. British Journal of Cancer, 2024, 130, 1239-1248.	2.9	0